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ABBREVIATIONS 
AKI Acute kidney injury 
Asc Ascorbate 
ATP Adenosine triphosphate 
CL Cardiolipin 
CyC Cytochrome c 
ΔΨm Mitochondrial membrane potential 
DFA Deferoxamine 
DFX Deferasirox 
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DNA Deoxyribonucleic acid 
DTPP Dodecyltriphenylphosphonium 
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FDA Food and Drug Administration 
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ICU Intensive care unit 
ISMP Institute for safe medical practices 
µM µmol/l 
mPTP Mitochondrial permeability transition pore 
NADH Nicotinamide adenine dinucleotide 
nm Nanometer 
NSAID Non-steroidal anti-inflammatory drug 
OK Opossum kidney 
PBS Phosphate buffered solution 
PT Proximal tubule 
RIFLE Risk, Injury, Loss, Failure, End-stage 
ROS Reactive oxygen species 
STED Stimulated emission depletion 
STORM Stochastic optical resolution microscopy 
TMRM Tetramethylrhodamine methyl ester 
TMPD Tetramethylphenylenediamine 
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1 INTRODUCTION 
1.1 The kidney as a critical target organ of drug toxicity 
The kidney plays a central role in ensuring homeostasis in the body. Besides ensuring 
excretion of toxins together with the liver and the gastrointestinal tract, the kidney regulates 
blood pressure, acid-base balance, electrolyte concentrations and the volume of 
extracellular fluids. These tasks are achieved by glomerular filtration, tubular reabsorption 
and tubular secretion1. 
Impairment of renal function can therefore lead to an increased patient morbidity and 
mortality2, 3. Acute kidney injury (AKI, formerly defined as acute renal failure) is a syndrome 
of abrupt loss in kidney function leading to an accumulation of products of nitrogen 
metabolism and/or decreased urine output, which is not always present1. Large variations 
of the incidence of AKI from 1 % to 31 % and the associated mortality (19 % - 83 %) have 
been reported, due to a lack of a consensus in the definition of AKI4-6. Therefore, in 2004 
the Acute Dialysis Quality Initiative formulated the Risk, Injury, Failure, Loss and End-stage 
kidney (RIFLE) classification7 (Table 1). It defines three stages of injury (risk, injury and 
failure) and two outcomes (loss and end-stage kidney disease). 
 
Table 1: RIFLE (Risk, Injury, Failure, Loss, End-stage) classification for AKI7, 8 
Class Glomerular filtration rate (GFR) 
criteria 
Urine output criteria 
Risk Serum creatinine x 1.5 
>25 % GFR decrease 
< 0.5 ml/kg/hour x 6 hours 
Injury Serum creatinine x 2 
>50 % GFR decrease 
< 0.5 ml/kg/hour x 12 hours 
Failure Serum creatinine x 3 or ≥ 4mg/dl with 
an acute rise < 0.5 mg/dl 
>75% GFR decrease 
< 0.3 ml/kg/hour x 24 hours 
or anuria x 12 hours 
Loss Loss of kidney function > 4 weeks  
End-stage 
kidney disease 
End-stage kidney disease > 3 months  
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Using unified criteria for staging kidney injury led to less variable numbers confirming that 
AKI is a global public health concern affecting around 13.3 million patients per year9. Among 
all hospitalized patients AKI has an incidence varying between 1-9 % depending on the 
population10. Especially critically ill patients (ICU - intensive care unit - patients) have a high 
incidence of 67 % in developing kidney injury8. 
Twenty percent of all kidney injuries are induced by drugs while hospital-acquired infections, 
sepsis, administration of radiocontrast and complex surgery are other factors for developing 
AKI11. 
The kidney is highly susceptible to injury due to several unique physiological features of this 
organ. Although only constituting 1  -2 % of the total body mass, the kidney receives 1200 
ml/ min of blood (20  -25 % of cardiac output)12. Taken together with the filtration of 180 l 
per day in the glomeruli, the kidney has a higher exposure to toxicants compared to other 
tissues in the body. Especially cells in the proximal tubule (PT) have a very high exposure 
due to the large surface area, formed by microvilli, and the enormous capability of 
reabsorption. Of the 180 l of primary filtrate, approximately 65 % is reabsorbed in the PT13. 
The large number of transporters expressed at the apical and basolateral side in the PT 
cells and the ability to concentrate solutes enhances the chance of drug accumulation and 
consequently cytotoxicity14. Furthermore, biotransforming enzymes expressed in the 
kidney, such as P459 monooxygenases, flavin containing monooxygenases and 
glutathione transferases, can convert drugs into toxic metabolites. The structure and the 
physiology of the PT will be described in the following chapter, since the PT is primarily the 
target in drug induced nephrotoxicity.  
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1.2 The renal proximal tubule 
Each of the two human kidneys contains 900000 to 1 million nephrons, the functional unit 
of the kidney15. Each nephron consists of the glomerulus, the PT, loop of Henle, distal tubule 
and the collecting duct (which is shared with other nephrons)16. The PT extends from the 
urinary pole of the glomerulus to the descending thin loop of Henle ( Figure 1).  
 
Figure 1: Structure of the nephron and examples for drug induced nephrotoxicity. (modified after 
Vaidya et al16) 
Anatomically the PT can be divided into pars convoluta, which is located in the cortical 
labyrinth and pars recta, which descends through the medullary ray into the outer stripe of 
the outer zone of the medulla17. A different classification into three parts can be made when 
PT segments are characterized by their ultrastructure as first described by Suzuki18, using 
light microscopy, and Sjostrand19, using additionally fluorescence microscopy. The first part 
(S1) ranges from the glomerulus and transitions slowly into the second (S2) segment, which 
ranges from the end of the convoluted part until the beginning of pars recta. The change 
into the third segment (S3) occurs abruptly. Epithelial cells in S1 are slightly taller than cells 
in S2, due to their extensive apical brush border. Furthermore, S1 cells interdigitate more 
extensively and have a very high number of mitochondria that are arranged in a palisade-
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shaped manner and are closely enwrapped by the basolateral membrane, the location of 
the sodium potassium ATPase. This is indicative of the high energy demand in these highly 
active transporting cells. Cells in S3 have a cuboidal shape, interdigitate little and have 
fewer, more randomly distributed mitochondria20 (Figure 2). 
 
 
Figure 2: Classification of the PT into three segments using ultrastructure. The diagram illustrates 
the differences of the three PT segments S1, S2 and S3 in terms of cell shape, distribution and 
number of mitochondria (M), lysosomes (L), endocytic vacuoles (E) and peroxisomes (P). Below are 
the according electron micrographs from the rat kidney. Taken from Maunsbach, Christensen chapter 
2 in renal physiology 20. 
 
The morphological features of the epithelial cells in the PT – energy demanding cells with 
a very well-developed transport machinery - already point towards the most important 
physiological function: reabsorption and secretion. Along the nephron the PT is responsible 
for reclaiming 65 % of the primary urine, whereas the distal tubule accounts for 30 % and 
the collecting duct for only 4 %13.  The driving force in proximal tubular reabsorption is the 
sodium flux through the cell21, 22. In the 1970’s, using in vivo micropuncture, Gyory and Kinne 
showed that blocking of the sodium potassium ATPase, which is located on the basolateral 
side of the PT cell23, 24, with ouabain abolished reabsorption of sodium and any fluid in PTs25. 
The sodium potassium ATPase constantly removes sodium from the epithelial cell, which 
generates a concentration gradient favouring sodium entry from the primary urine into the 
cell. Along with water that is moving passively through the cell due to the sodium gradient 
(via water channels called aquaporins), other transporters facilitate the apical uptake of 
molecules. All of the filtered glucose and amino acids are reabsorbed in the PT by 
secondary active transport through cotransporters driven by the sodium flux from urinary to 
interstitial side. Responsible for the uptake of glucose and sodium into the PT cell is the 
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high-capacity, low affinity sodium and glucose cotransporter SGLT2, which is almost 
exclusively found in apical membranes of PTs (S1,S2 segments)26-28. 
Similarly, 80 % of filtered phosphate is reabsorbed apically by the PT expressed sodium 
driven cotransporters NaPi-IIa and NaPi-IIc29, 30. The expression of NaPi-IIa gradually 
decreases over the PT, whereas NaPi-IIc was not identified in S3 segments29, 31. 
The PT also plays an important role in the reuptake of bicarbonate, as 80% of the filtered 
bicarbonate is reabsorbed by the PT. The apical located sodium proton antiporter leads to 
a luminal secretion of one proton, which, catalysed by carbonic anhydrase IV, reacts with 
bicarbonate to CO2 and water. CO2 can diffuse into the PT cell where it is metabolized by 
carbonic anhydrase II to bicarbonate and finally exported on the basolateral side via the 
sodium bicarbonate cotransporter kNBC1. 
65 % of filtered potassium is reabsorbed passively via solvent drag or diffusion. Chloride 
and calcium are also transported paracellularly. Water can also be reabsorbed 
paracellularly and transcellularly via water channels (aquaporins, AQP-1). 
Upon damage of PT cells (renal Fanconi syndrome, see detailed explanation in chapter 
1.4), the important role of the uptake of certain molecules becomes clear, as it is 
characterized by a urinary loss of glucose, amino acids, phosphate and bicarbonate (Figure 
3). No other segment in the nephron can compensate for the uptake of these molecules. 
 
 
 
Figure 3: Reuptake of glucose, amino acids, phosphate and bicarbonate is mainly performed by the 
PT (diagram). The uptake of the solutes is coupled to the sodium gradient across the cell that is 
maintained by the sodium potassium ATPase (right: schematic display of important transporters)13. 
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Another very important process in the PT is the reuptake of filtered low molecular weight 
proteins (LMWP), like insulin, parathyroid hormone and retinol binding protein32. The 
reuptake ensures that these proteins are not lost in the urine and that distal parts of the 
nephron are not exposed to bioactive proteins. The uptake of LMWPs is mostly facilitated 
by the low-affinity, high-capacity uptake system of the two receptors megalin and cubilin33, 
34. Megalin, identified in 1982, is a large 600 kDa glycosylated receptor35 and belongs to the 
low-density lipoprotein receptor family35, 36. Megalin is expressed in the apical membrane of 
the PT and was also found to be present in endocytic vesicles37. Extrarenal absorptive 
epithelia like the choroid plexus, lung alveoli, ciliary body, retinal epithelium of the eye, gall 
bladder, placenta, parathyroid glands and thyroid gland also express megalin38. Cubilin, a 
460 kDa glycosylated extracellular protein, is believed to be responsible for ligand binding39. 
Cubilin is thought to interact with membrane proteins for membrane localization and 
endocytosis40. In the PT cubilin supposedly interacts with megalin (both share a number of 
ligands) forming a multireceptor complex driving the internalization of the bound ligands and 
the complex itself (receptor mediated endocytosis)41. The endosomes formed are then 
acidified to promote dissociation of the ligand and the receptors can be recycled to the 
luminal membrane42, 43. 
Along with the liver, the kidney is heavily involved in the elimination of drugs, with around 
32 % of drugs currently used in the US showing renal elimination greater than 25 %44. 
Elimination can occur via glomerular filtration or tubular secretion, or a combination of both. 
For the transcellular transport of drugs from the blood through the PT into the urine, drugs 
need to enter the PT cell via the basolateral membrane and exit via the apical side. In many 
cases this process does not happen passively, but involves transporter proteins, that can 
facilitate a transport against concentration gradients. The transporters being suspected to 
be involved in drug transport can be separated into cationic transporters (Table 2), anionic 
transporters (Table 3), transporters with less or unknown specificity in substrate charge ( 
Table 4) and ABC efflux transporters ( 
Table 5)45. It is important to consider that the expression site of these transporters is often 
not limited to a single location in the body46. 
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Table 2: List of cationic transporters expressed in the kidney45 
Transporter Expression Substrates 
SLC22A1 
OCT1 
Basolateral 
(influx) 
prostaglandin E2, choline, morphine, tetraethyl 
ammonium, metformin, acyclovir, lamivudine 
SLC22A2 
OCT2 
Basolateral 
(influx) 
creatinine, dopamine, histamine, prostaglandin E2, 
tetraethylammonium, pancuronium, MPP, lamivudine 
SLC22A3 
OCT3 
Basolateral 
(influx) 
5-HT, noradrenaline, dopamine, quinidine, tetraethyl 
ammonium, MPP 
SLC47A1 
MATE1 
Apical (efflux) Creatinine, thiamine, cimetidine, quinidine, paraquat, 
cephradine, cephalexin 
SLC47A2 
MATE2K 
Apical (efflux) Creatinine, thiamine, cimetidine, MPP, metformin, 
aciclovir 
 
Table 3: List of anionic transporters expressed in the kidney45 
Transporter Expression Substrates 
SLC22A6 
OAT1 
Basolateral 
(influx) 
Aminohippuric acid, estrone sulfate, raltegravir, 
tenofovir, zidovudine 
SLC22A7 
OAT2 
Basolateral 
(influx) 
Aminohippuric acid, prostaglandine E2, estrone sulfate, 
paclitaxel, 5-fluorouracil, allopurinol, zidovudine 
SLC22A8 
OAT3 
Basolateral 
(influx) 
Aminohippuric acid, estrone sulfate, raltegravir, 
tenofovir, zidovudine 
SLC22A11 
OAT4 
Apical 
(bidirectional) 
Dehydroepiandrosterone, estrone sulfate, uric acid, 
zidovudine 
SLC22A12 
URAT1 
Apical 
(bidirectional) 
Uric acid, orotic acid 
SLCO4C1 
OATP4C1 
Basolateral 
(influx) 
Steroid conjugates, thyroid hormones, digoxin, ouabain, 
penicillin 
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Table 4: List of transporters with no specificity for substrate charge expressed in the kidney45 
Transporter Expression Substrates 
SLC15A1 
PEPT1 
Apical (influx) Oligopeptides, cyclacillin, valacyclovir, cefadroxil 
SLC15A2 
PEPT2 
Apical (influx) Oligopeptides, beta-lactam antibiotics, fosinopril 
SLC28A1 
CNT1 
Apical (efflux) Nucleosides, ribavirin, gemcitabine, zidovudine, 
zalcitabine 
SLC28A2 
CNT2 
Apical (efflux) Nucleosides, didanosine, cytidine 
SLC28A3 
CNT3 
Apical (efflux) Nucleosides, zidovudine, zalcitabine, didanosine 
SLC29A1 
ENT1 
Basolateral 
(bidirectional) 
Nucleosides, ribavirine, 2’,3’-Dideoxyinosine 
SLC29A2 
ENT2 
Basolateral 
(bidirectional) 
Nucleosides, 2’,3’-Dideoxyinosine 
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Table 5: List of ABC efflux transporters expressed in the kidney45 
Transporter Expression Substrates 
ABCB1     P-
gp 
Apical (efflux) Steroids, lipids, bilirubin, bile acids, digoxin, doxorubicin, 
maraviroc, HIV protease inhibitors 
ABCC1 
MRP1 
Basolateral 
(efflux) 
Prostaglandins, folic acid, bilirubin, anticancer drugs, 
HIV protease inhibitors 
ABCC2 
MRP2 
Apical (efflux) Bilirubin, estradiol, glucuronide, estrone sulfate, 
methotrexate, etoposide, valsartan, HIV protease 
inhibitors 
ABCC3 
MRP3 
Basolateral 
(efflux) 
Bile salts, estradiol glucuronide, anticancer drugs 
ABCC4 
MRP4 
Apical (efflux) Taurocholic acid, cAMP, cGMP, urate, prostaglandins, 
methotrexate, furosemide 
ABCC6 
MRP6 
Basolateral 
(efflux) 
Anticancer drugs 
ABCC10 
MRP7 
Unknown Estradiol glucuronide, paclitaxel, tariquidar, tenofovir, 
nevirapine 
ABCG2 
BCRP 
Apical (efflux) Estrone sulfate, porphyrins, anticancer drugs, 
conjugated organic anions 
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1.3 Mitochondria – the indispensable energy supplier in the 
proximal tubule 
The kidney is second only to the heart in mitochondrial number and oxygen consumption.47 
The main function of the PT, the transport of solutes, is a very energy demanding process, 
which makes the PT cells highly dependent on mitochondria, the energy factory of the cell. 
Mitochondria in PT cells are numerous and are enwrapped in basolateral infolds, located in 
close proximity to the sodium potassium ATPase, the main energy consumer.  
 
Mitochondria are intracellular organs present in every cell of the human body, except 
erythrocytes, and are of endosymbiotic origin, which is visible by the existence of two 
membranes, the outer and the inner membrane. The outer membrane is a simple 
phospholipid bilayer, which has a high permeability due to existing porins, facilitating easy 
exchange of, for example, nutrients or ADP/ATP. The infolded inner mitochondrial 
membrane (cristae), which in addition to phosphatidylcholine also contains cardiolipin48, 
incorporates complex structures and is the location of the respiratory chain complexes and 
transport proteins (for example transporter of the inner membrane TIM49). The cristae allow 
an efficient assembly of the different complexes and can help to locally accumulate 
molecules from the mitochondrial matrix50. 
Traditional theory claims that the primitive obligate aerobe structure - the precursor of the 
mitochondrion possibly similar in physiology to the modern Rickettsia species - was 
acquired by an anaerobic nucleus-bearing cell via phagocytosis51. The mitochondria not 
only provided energy for the host, but also served as detoxifier as they removed oxygen 
from the cell. An alternate theory claims that the host was an archaebacterium that engulfed 
the ancestral mitochondrion, a facultative anaerobe, similar to the still existing 
Rhodobacterials52, 53. Here the benefit for the archaebacterial host originated in the 
mitochondrion providing electrons and H2 as a source of energy54. How the facultative 
anaerobe was taken up into the archaebacterium remains unclear. 
 
1.3.1 Generating energy in mitochondria 
ATP, the chemical energy equivalent in the cell, is generated from ADP and HPO4- by the 
mitochondrion via oxidative phosphorylation. This reaction is catalyzed by complex V, the 
ATP synthase, which is fuelled by the proton gradient across the inner mitochondrial 
membrane. The proton gradient is built up by complex I, III and IV during the electron 
transport chain, with the final reaction of oxygen to water. For the generation of the redox-
equivalents NADH and FADH2, fuel molecules, such as glucose, fatty acids and amino 
acids, are broken down to acetyl CoA. Acetyl CoA enters the citric acid cycle, where during 
several steps NAD+ and FAD2+ are reduced to NADH and FADH2 and oxaloacetate is 
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generated, which serves as an acceptor for acetyl CoA. NADH and FADH2 are oxidized by 
complex I and II, respectively. The electrons donated by the redox-equivalents are then 
shuttled from complex I or II by ubiquinone (coenzyme Q10) to complex III. From there 
electrons are passed on to cytochrome c, which then donates the electrons to complex IV 
(cytochrome c oxidase). The electrons are then passed onto oxygen reducing it to water 
(together with protons). During the electron transport complexes I, III and IV pump protons 
from the matrix into the intermembrane space, generating an electrochemical proton 
gradient; also called proton motive force. This gradient explains why the mitochondrial 
matrix is negatively charged in comparison to the cytosol, the so called mitochondrial 
membrane potential (ΔΨm approximately 150 mV)55. The ATP synthase uses the movement 
of protons along the electrochemical gradient to generate ATP from ADP and HPO4- (Figure 
4). The energy that was generated from breaking down bonds of carbon and hydrogen 
based organic fuels was converted into energy stored in ATP via chemiosmotic coupling. 
Energy can be released by the reaction of ATP to ADP, as for example performed by the 
sodium potassium ATPase56. 
 
 
Figure 4: Scheme of oxidative phosphorylation. NADH and FADH2 are oxidized by complex I and II, 
respectively. The donated electrons are then shuttled by ubiquinone (Q) to complex III. From there 
electrons are transferred to cytochrome c, where the electrons are passed on to complex IV and 
finally to oxygen reducing it to water (together with protons). Complexes I, III and IV are pumping 
protons into the intermembrane space, generating an electrochemical proton gradient, which fuels 
the generation of ATP by complex V (ATP synthase)57. 
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1.3.2 The role of iron in mitochondria 
Apart from the function of generating energy in the form of ATP, mitochondria play a central 
role in the metabolism of trace elements, especially iron. Iron is involved in many cellular 
processes such as energy metabolism, respiration and DNA synthesis. Iron has unpaired 
electrons which gives it the ability to donate or accept electrons. Therefore, iron is often 
incorporated as a prosthetic group in structural proteins and enzymes58. Along with the 
reactivity of iron the danger of enabling reactions that are harmful to the cell arises. As an 
example the generation of reactive oxygen species (ROS) can induce cell death59. Hence, 
a sophisticated mechanism has been developed in the cell to minimize the risk of toxicity, 
while maintaining metabolic reactions60. The gatekeeper for iron regulation and metabolism 
is the mitochondrion. 
Mitochondria utilize and accumulate iron, leading to a mitochondrial iron concentration twice 
as high as in the cytosol61. Iron as cofactor is part of heme-containing proteins, iron-sulfur-
cluster-containing proteins and iron ion containing proteins. Important heme containing 
proteins include succinate dehydrogenase (complex II), cytochrome bc1 (complex III), 
cytochrome c and cytochrome c oxidase (complex IV), which are all involved in the electron 
transport chain. Also involved in the electron transport chain are the iron-sulfur containing 
proteins NADH:ubiquinone oxidoreductase (complex I), subunits of succinate 
dehydrogenase (complex II), Rieske iron-sulfur protein (complex III) and electron-transfer 
flavoproteins62. Involved in other processes are the iron-sulfur-cluster-containing proteins 
aconitase (enzyme in the citric acid cycle), lipoic acid synthase (lipoic acid is a mitochondrial 
anti-oxidant63), biotin synthase (biotin is a coenzyme involved in the synthesis of fatty acids, 
isoleucine, valine and in gluconeogenesis64) and radical S-adenosylmethionine (SAM) 
enzymes (generation of radicals to functionalize non-activated C-H bonds65). Diiron 
monooxygenases and dioxygenases contain iron-ion cofactors. Members of the AlkB family 
of Fe(II)-and 2-oxyglutarate dioxygenases ALKBH1 and ALKBH7 are involved in 
mitochondrial-tRNA modification and regulation of necrosis, respectively66, 67. The large 
number of enzymes requiring iron as a cofactor demonstrates the importance of iron for 
mitochondria. 
 
Disturbance of the iron balance in mitochondria can negatively affect mitochondrial function 
and health. Deficiency in iron can decrease the activity of iron containing enzymes in 
mitochondria leading to an impaired respiration together with decreased levels of 
cytochrome and gluconeogenesis68, 69. Mitochondrial morphology can also be altered, 
presented by increased mitochondrial size, rounding up of the mitochondria and a loss of 
cristae70, 71. These changes can eventually also induce damage such as fragmentation of 
mitochondrial DNA72. 
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Similar to iron deficiency, iron overload can damage mitochondria. The elevated levels of 
iron can lead to increased levels of ROS, which can damage for example lipids causing a 
change of membrane fluidity and permeability73. Additionally, iron overload also induces a 
reduction of respiration, decreased expression of respiratory chain enzymes and damage 
of mitochondrial DNA74. High levels of cytosolic iron can affect the uptake of manganese, 
resulting in decreased activity of the mitochondrial manganese-dependent superoxide 
dismutase, an enzyme protecting against radicals generated from respiration75. These 
effects finally induce cell death, including iron-dependent ferroptosis76. 
 
1.3.3 Responding to stress in mitochondria: the mitochondrial 
permeability transition pore (mPTP) 
In response to stress mitochondria are thought to open the mitochondrial permeability 
transition pore (mPTP). The mPTP is an inner membrane structure that forms a 
nonselective channel77. This voltage-gated channel, controlled by a number of proteins, 
typically opens in response to ROS and calcium overloading78. The mPTP exhibits different 
permeabilities due to various opening times ranging from periods of milliseconds to 
seconds79. A full opening of the mPTP induces the release of matrix metabolites, like NAD+, 
glutathione and calcium, which results in an immediate loss of mitochondrial membrane 
potential, inhibition of oxidative phosphorylation, swelling of mitochondria and eventually 
rupture of the outer membrane and release of intermembrane space proteins78. This burst 
of metabolites into the cytosol damages proteins, nuclear DNA, transporters, ion channels 
and membrane phospholipids80, which induces cell death if the mPTP remains open81-83. 
The composition of the mPTP remains unclear, as knockout models of the suggested 
proteins forming the pore (in any combination) showed that none of cyclophilin D (CypD), 
the adenine nucleotide translocator (ANT), the outer membrane anion channel (VDAC), or 
the phosphate translocator (PiC) are essential78. Recently, either the subunit c of ATP 
synthase or a dimer of ATP synthase is believed to form the core of the mPTP. Definite 
proof of the composition and the existence of the mPTP remains a target of investigation79, 
82. Therefore, explaining mitochondrial swelling simply by suggesting mPTP opening has to 
be done cautiously. 
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1.4 Renal Fanconi Syndrome 
First observations of the specific proximal tubular dysfunction were made in 1903 by 
Abderhalden, who described a deposition of cystine crystals in liver and spleen of a 21-
month-old infant and named the disorder familial cysteine diathesis84. Similar cases in 
children with progressive wasting, rickets, dwarfism and renal disease where described 21 
years later by Lignac85. After describing in 1930 a child not only presenting with rickets and 
stunted growth, but also glucosuria and albuminuria, Fanconi recognized in 1936 the 
similarity between his case and the descriptions of deToni in 1933 and Debré in 1934 and 
suggested the term “nephrotic-glycosuric dwarfism with hypophosphatemic rickets” for the 
syndrome86-89. The name which is referred to as Lignac-de Toni-Debre-Fanconi syndrome, 
was reduced to Fanconi syndrome in 1943 by McCune90. 
 
Renal Fanconi syndrome is the result of a dysfunction of the PT resulting in an increased 
urinary excretion of substances that are exclusively or predominantly reabsorbed in the PT, 
namely glucose, amino acids, phosphate and bicarbonate91. Alongside with water a variety 
of solutes including sodium, potassium, calcium, magnesium, carnitine, lysozyme, 
enzymes, peptide hormones and immunoglobulin light chains, can also be lost during the 
occurrence of Fanconi syndrome. Due to the loss of phosphate a metabolic bone disease 
(bone demineralization) can develop as a secondary complication. Children with Fanconi 
syndrome fail to grow and present with a clinical picture of rickets, such as bowing 
deformities of the legs, frontal bossing, beading of the ribs and metaphyseal widening at the 
wrists, knees or ankles. Adults with acquired Fanconi syndrome suffer from osteomalacia, 
which is characterized by bone pain and spontaneous fractures92. 
The different onset times for Fanconi syndrome already make it clear that the origin of the 
syndrome is variable. The early onset is a sign of a hereditary source, whereas a late onset 
hints to an acquired Fanconi syndrome induced by nephrotoxic drugs or chemicals.  
Genetic forms of Fanconi syndrome can be categorized as (i) accumulation of a toxic 
metabolite, (ii) disruption of cellular energy supply or (iii) disruption of intracellular 
transport93. The deposition of cystine as described by Abderhalden in 1903 and Fanconi in 
1936 is one example for the accumulation of a toxic metabolite; in these cases patients 
suffered from cystinosis where a mutation of the CTNS gene coding for the lysosomal 
cysteine transporter cystinosin causes the accumulation of cystine in the lysosomes94. 
Other examples of genetic diseases that involve accumulation of toxic metabolites are 
tyrosinaemia (disturbed breakdown of tyrosine), galactosaemia (disturbed breakdown of 
galactose 1-phosphate), Fanconi-Bickel (mutation of the glucose transporter 2 leading to 
accumulation of glycogen in liver and kidney), hereditary fructose intolerance (deficiency in 
fructose 1-phosphate aldolase causes increased amounts of fructose 1-phosphate after 
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fructose ingestion) and Wilson’s disease (copper accumulation)92. Mitochondrial 
cytopathies such as the Pearson and MELAS (mitochondrial encephalomyopathy with lactic 
acidosis and stroke-like episodes) syndromes, induce the Fanconi phenotype by disrupting 
energy supply. Another genetic form of Fanconi syndrome causing mitochondrial 
dysfunction, was described recently. A missense mutation in the third codon of the 
peroxisomal protein EHHADH targets the EHHADH to mitochondria, where the protein is 
incorporated into mitochondrial trifunctional protein causing disturbance of β-oxidation of 
long chain fatty acids. Additionally, mutated EHHADH limits the activity of respiratory 
complex I, resulting in decreased oxidative phosphorylation, mitochondrial membrane 
potential maintenance and ATP generation. This leads to a diminished function of the 
sodium potassium ATPase restricting the cellular uptake and extrusion95. 
Interference with the uptake machinery in the PT occurs, for example, with the 
oculocerebrorenal (Lowe) syndrome (mutation in the OCRL1 gene leads to disturbed 
interaction of the protein with clathrin and therefore to dysregulated protein trafficking 
between endosomes and the Golgi network)96, or in Dent’s disease 1 where a mutation in 
the gene encoding for the chloride transporter ClC5 leads to an insufficient acidification of 
endosomes, and therefore impaired receptor recycling for endocytosis97. In addition to these 
systemic disorders isolated forms of Fanconi syndrome (Fanconi renotubular syndrome 1-
3) have been reported and are still under investigation93. 
In contrast to hereditary forms of Fanconi syndrome, acquired Fanconi syndrome can occur 
at any point in life. Apart from the biggest risk factor of drug induced Fanconi syndrome, 
environmental toxins, abnormal proteins and immunological disorders contribute to the 
number of acquired Fanconi syndromes. Among environmental toxins heavy metals are one 
of the main causes of the disease. Contamination of soil and rice with cadmium after the 
second world war, for example, led to an increased number of cases of itai-itai or “ouch-
ouch” disease, which is characterized by a loss of PT function and osteomalacia98. 
Cadmium and uranium are both more toxic than lead and mercury, but heavy metal induced 
nephrotoxicity is due to an accumulation of the metal that then interferes with the transport 
processes in the PT. Exposure to platinum usually only occurs during chemotherapeutic 
treatment of carcinoma with cisplatin, which is a known cause for Fanconi syndrome. 
Accumulation of abnormal plasma proteins can occur with multiple myeloma, amyloidosis, 
light chain nephropathy and benign monoclonal gammopathy92. Filtered immunoglobulin 
light chains are reabsorbed in the PT via endocytosis and, in excess amounts, are toxic to 
the PT. 
     
By far the most frequent cause for acquired Fanconi syndrome is drug toxicity. This is not 
only a huge burden for the patients themselves, but also limits the efficacy and usage of 
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otherwise effective therapies. The list of drugs and chemicals inducing Fanconi syndrome 
is huge and unfortunately continues to grow (Table 6), with the most common drugs being 
anti-cancer agents, antivirals and aminoglycoside antibiotics99. The PT cell takes up many 
of the drugs circulating in the bloodstream by various transporters, such as organic anion 
and cation transporters and p-glycoprotein100. This leads to elevated concentrations of the 
drugs in the PT cells compared to all other cells in the human body – with the exception of 
hepatocytes. The mechanisms of how the accumulation induces PT dysfunction are not well 
studied and can differ between drugs although resulting in the same clinical phenotype. 
 
Table 6: List of drugs inducing Fanconi syndrome91 
Class Drugs Indication 
Alkylating agents Ifosfamide Cancer 
Aminogycoside Antibiotics Gentamicin, Amikacin Gram-negative bacterial 
infection 
Anti-epileptics Sodium valporate Seizures, bipolar disorders 
Anti-protozoals Suramin Trypanosomiasis 
Dicarboxylic acids Fumaric acid Psoriasis 
Iron chelators Deferasirox Iron overload 
NRTIs Didanosine, Stavudine HIV 
NtRTIs Tenofovir, Adefovir, 
Cidofovir 
HIV, Hepatitis B, CMV 
Platinum compounds Cisplatin/carboplatin Cancer 
Salicylates Aspirin Analgesia, anti-
inflammatory 
Tetracycline antibiotics Degraded tetracycline Bacterial infection 
Tyrosine kinase inhibitors Imatinib mesylate Chronic myeloid leukemia 
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Platinum containing compounds and alkylating agents are indicated as therapy against 
cancer and are known to induce PT injury101. Within one class of agents different shades of 
toxicity exist. Cisplatin, for example, is more toxic than the related compound carboplatin, 
due to its greater uptake into the PT cells. Carboplatin in a concentration 10 times higher 
than a toxic concentration of cisplatin did not cause injury in a PT cell model102. The 
alkylating agent ifosfamide was shown to be rapidly taken up into the PT via organic cation 
transporters, where it is metabolized to toxic chloracetaldehyde103. 
An emerging problem in causes of renal Fanconi syndrome are anti-viral drugs. In the 
treatment of infections with HIV, antiviral drugs need to be taken lifelong. The chronic 
exposure leads to increased levels of the drug in the kidney, increasing the risk for 
nephrotoxicity. The nucleotide reverse transcriptase inhibitors adefovir, cidofovir and 
tenofovir are probably entering the PT cell via organic anion transporters104, 105. Due to the 
high risk of adefovir and cidofovir in inducing renal Fanconi syndrome, tenofovir has been 
developed as a safer alternative. However, numerous cases reporting renal Fanconi 
syndrome occurred upon tenofovir treatment, although the majority of patients might 
develop minor tubular defects that remain undetected at first106, 107. A mitochondrial 
involvement in the mechanism of tenofovir associated nephrotoxicity seems likely, since 
mitochondrial damage, in the form of grossly enlarged organelles, has been reported in 
patient biopsies108.  
Treatment of bacterial infections with aminoglycosides is effective but limited to the 
nephrotoxicity of these drugs. Within the class gentamycin appears to be more toxic than 
tobramycin and amikacin109. Unfortunately, infections with multi-resistant bacteria require 
the use of reserve antibiotics (for example Polymyxin B, a polypeptide antibiotic and known 
to cause kidney injury110, 111) or combinations of different antibiotics, which increases the 
risk of toxicity. Due to their uptake by endocytosis via megalin, aminoglycosides and 
polymyxins not only cause kidney injury, but also affect the inner ear with their ototoxicity 
(megalin is also expressed there explaining the accumulation in kidney and ear)112, 113.  
Other agents inducing Fanconi syndrome include suramin, tyrosine kinase inhibitors and 
salicylates91. The latter have been reported to interfere with mitochondrial function and the 
induction of mitochondrial swelling114-116. 
Relatively new in the field of Fanconi syndrome inducing drugs is the iron chelator 
deferasirox (DFX). In the first year after approval and release on the market, DFX was 
ranked second on the list of drug associated patient deaths by the Institute for safe medical 
practices (ISMP)117, due to the unknown side effect of nephrotoxicity. The mechanism of 
toxicity is as yet unknown, wherefore this study investigated the effect of DFX on the PT. 
 
Introduction  
22 
1.5 Deferasirox (DFX) 
DFX is a relatively new, tridentate iron chelator, that was approved by the FDA in 2005 and 
one year later by the European Medical Agency118, 119. The goal in the development of DFX 
was to improve the therapy for removing non transferrin bound iron by designing an iron 
chelator that can be administered orally120. The treatment of β-thalassemia (a defect in the 
β-globin chain of haemoglobin leads to an accumulation and precipitation of α-globin in red 
blood cell precursors resulting in anaemia) relies on blood transfusion121. As a result of the 
transfusions and the inability of the human body to actively excrete iron,  the amount of iron 
increases to lethal levels, wherefore iron chelation therapy is needed122. The introduction of 
deferoxamine (DFA, Figure 5) in 1963 as the first iron chelator used in thalassemia marked 
a breakthrough in the therapy of these patients, as the reduced iron burden lead to a 
reduced iron-related morbidity and mortality123. DFA mobilizes the iron storages by binding 
solubilized iron and shifting the balance between the free and the insoluble hemosiderin, 
the insoluble deposition form of iron124. The chelated, now solubilized iron can then be 
excreted. Although DFA is efficient in removing iron, there are some drawbacks due to the 
bioavailability of the drug. The short plasma half-life and the poor oral bioavailability, require 
slow subcutaneous or intravenous infusions daily, as plasma levels of the drug only remain 
elevated during the perfusion120.  
In 1980 desferrithiocin (Figure 5) was isolated from Streptomyces antibioticus and was 
found to be a potent iron chelator with oral bioavailability125. Although single doses did not 
seem to cause toxicity, desferrithiocin did cause nephropathy in a subchronic 10 day study 
in rats and induced degenerative changes in the PT. Since nephrotoxicity also occurred in 
dogs, further development of desferrithiocin was stopped in 1986121.  
Parallel to the continuing efforts to create an orally available iron chelator similar to 
desferrithiocin with less severe side effects by the oral chelator program of Ciba (now 
Novartis), the iron chelator deferiprone (DFP, Figure 5) was discovered in 1993, before 
being approved by the European Medical Agency (1999) and the FDA (2011) 120, 126. DFP 
appears to be less efficient in chelating iron and is used if an inadequate response to other 
chelators occurred or in case of severe iron overload in combination with another iron 
chelator. The main side effects of DFP do not involve nephrotoxicity, but are agranulocytosis 
and hepatic fibrosis, as DFP seem to redistribute the iron towards the liver127, 128. 
Unfortunately DFP has the disadvantage of achieving therapeutic plasma levels only by 
administering the drug every 6 hours120.  
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Figure 5: Chemical structure of different iron chelators. DFA has to be administered subcutaneously 
or intravenously. DFP can be taken orally but has to be taken every 6 hours. DFX was developed 
based on the chemical structure of desferrithiocin – a natural occurring iron chelator with severe 
nephrotoxicity – and can be taken orally once a day. 
 
Further work in the oral iron chelator program, lead to the discovery that bis-hydroxy-phenyl 
triazole is the ideal basic structure for an oral iron chelator, which allows ideal positioning 
of the hydroxyl-groups and the coordinating nitrogen. The central coordinating nitrogen in 
the tridentate chelator backbone is the feature that is shared with desferrithiocin. Among 
the huge number of tested compounds with similar chemical features (many of them barely 
water soluble), ICL670 (DFX, Figure 5) was found to be generally well tolerated in rat and 
Marmoset making DFX the most promising candidate121 and was designated an orphan 
medicine by the European Medical Agency in 2002. DFX was shown to be more effective 
in chelating iron – especially rapid chelation occurred in the kidney - than DFA and DFP in 
iron-overloaded rats121. The excretion of DFX appeared to be mainly via the bile (urinary 
excretion was only observed after a large dose), whereas DFA is known to be excreted 
mainly via the urine and for iron chelated in hepatocytes via feces. Similar results were also 
observed in iron-overloaded Marmosets, showing a higher efficiency of DFX in chelating 
iron than DFA and DFP129. In rats DFX accumulates in the kidney cortex (631 nmol/g) 
compared to blood levels (213 nmol/mg), which is most likely the explanation for the PT 
specific toxicity130. In the first clinical studies no major side effects occurred in healthy and 
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thalassemic patients, while the excretion occured, as studied before, via feces131, 132. DFX 
in a concentration of 20 mg/kg/day was shown to be as effective as 40 mg/kg/day DFA133. 
A mild increase of urinary protein excretion was observed in a 6-month clinical trial, 
indicating mild effects on the kidney.  
DFX and the DFX-iron complex are 98.2 % – 99.6 % bound to plasma proteins. In humans 
DFX showed a bioavailability of 70 %. After daily dosing of 20-30 mg/kg therapeutic 
concentrations ranging from 100-200 µM can be achieved. Amongst all patients 
investigated during clinical studies 36.3 % showed serum creatinine increases over 33 % 
at no less than two consecutive visits. A dose reduction could restore normal kidney 
function. Therefore, it was suggested that the adverse effects were caused by an 
overchelation130. 
The most relevant findings regarding adverse effects of DFX was nephropathy consisting 
of tubular degeneration, cytoplasmic vacuolization of cortical tubular epithelial cells and 
tubular necrosis, which was observed in all investigated species. 
The problem of nephrotoxicity induced by DFX is still debated since long-term studies are 
missing134. At least the increase in DFX-associated deaths led regulatory agencies to 
require a boxed warning on prescription information of DFX in 2010119. The nephrotoxicity 
manifests as renal Fanconi syndrome, a generalized dysfunction of the PT. The onset of 
Fanconi syndrome after the start of DFX therapy has a mean of 17.8 months (1 – 36 month 
range) and is reversible within 3 weeks of discontinuation of the drug (3 days to 6 weeks), 
whereby it is more common to occur in very young (≤ 16 years) and elderly patients (≥ 65 
years)135-140. 
In summary, the discrepancy among different studies concerning the incident of kidney 
toxicity upon DFX treatment is founded in the lack of a generalized system of evaluating 
kidney function and the definition of different thresholds defining toxicity119. Biomarkers 
used, such as serum creatinine, lack sensitivity and only increase after severe damage has 
occurred. Therefore, it is still necessary to improve methods for detection of kidney injury. 
Developing a better understanding of how renal toxicity develops can aid in identifying an 
early marker141. 
 
The focus of this study is to identify the mechanism of DFX toxicity. The main issues are 
why toxicity is localized to the PT, and whether and why the toxicity is an off-target effect or 
related to the chelation of iron. Comparing DFX toxicity to nephrotoxicity of, for example, 
tenofovir might be misleading, since both molecules possess different structures. 
Nevertheless, a general feature of PT specific damage is accumulation of drugs that are 
excreted by tubular secretion. This grants access to the PT cell and the potential to 
accumulate. Furthermore, an interference with mitochondria could lead to a transport 
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dysfunction. Since iron is very important in mitochondria (see 1.3.2), DFX might induce 
Fanconi syndrome via mitochondrial toxicity. DFX can also enter cells easily due to its high 
lipophilicity. Contradicting a tubular secretion is the fact that only a small percentage of DFX 
is eliminated urinarily, although the high affinity for binding plasma proteins makes a case 
for tubular secretion. Additionally, it has to be ruled out whether a metabolite of DFX is the 
trigger for toxicity (although most of the circulating drug remains unmetabolized). In 
preclinical studies an involvement of organic anion and cation transporters was already 
ruled out, but there is still a possibility of DFX being a substrate for MRP2. Furthermore, an 
investigation of DFX toxicity should also consider whether residues of the manufacturing 
process of DFX cause kidney toxicity (Figure 6). The educts of DFX include salicylic acid, 
which belongs to the group of non-steroidal anti-inflammatory drugs (NSAIDs), that are 
known to damage the kidney. 
 
 
 
Figure 6: Synthesis of DFX in a twostep process. Salicylic acid and salicylic amide condensate 
mediated by thionylchloride to hydroxyphenylbenzoxazinone. After activation this intermediate reacts 
with hydrazines forming DFX (4-[3,5-Bis-82-hydroxyphenyl9-1,2,49triazol-1-yl]-benzoic acid). Taken 
from Nick et al. 2003121 
 
 
Introduction  
26 
1.6 Live imaging as an investigative tool for determining drug 
toxicity 
Cell and animal models are used for the estimation of toxicity during drug development. The 
readout for the in vitro assays is often cell viability measured by ATP levels or membrane 
integrity142, 143. Those assays can be applied in a high-throughput manner, allowing 
screening of a huge number of drug candidates. However, minor changes in cell metabolism 
are often missed since they do not directly cause cell death. Therefore, once chemicals are 
developed further and tested in animal studies, the metabolic changes on a cellular level 
become visible, causing toxicity in the animal. To further reduce the number of animals used 
for toxicity testing and to lower the costs in drug development, it would be beneficial to 
already have a better, high-throughput applicable readout predicting toxicity. Advances 
made in imaging techniques and image processing tools enabled a high content screening, 
where multiple markers of cell health and metabolism can be read simultaneously144. This 
allows predictions of toxic effect with a high sensitivity and a low false positive rate. In 
addition, the changes detected already indicate the intracellular location of toxicity. 
Combining imaging techniques and improvement of cell models can enhance the safety in 
drug development in an early stage, although the interrelationship between the organs has 
still to be modelled in animal and in human clinical trials. 
The main techniques used in this study for the investigation of the effects of DFX on the 
kidney were confocal and multiphoton microscopy. 
 
1.6.1 Confocal microscopy 
Confocal microscopy is a form of fluorescence microscopy that can be used to study fixed 
or living cells. Fluorescence microscopy is based on the phenomenon that electrons of 
certain molecules (so called fluorophores) can get excited to a higher state by absorbing a 
photon of a certain wavelength. To return to ground state the excess energy is emitted by 
light in a longer wavelength than the excitation wavelength (Stoke’s shift), and by vibration 
or heat145, 146 (Figure 8 A). In widefield microscopy the whole sample is illuminated and 
fluorescence signals from all positions in the sample are collected limiting the resolution. In 
confocal microscopy the excitation light is focused into a single spot in x,y direction by the 
use of a pinhole ( the whole z direction remains illuminated). Emitted light is passed through 
further lenses and filters removing possible contaminations of different fluorophores. After 
passing through a pinhole, which removes out of focus fluorescence, the collected photons 
hit the detector where the signal is converted into an electrical signal, enhanced and with 
the aid of imaging software displayed as a digital image147 (Figure 7). Detectors convert the 
energy of the incoming photons into electrical energy by a photocathode and enhances the 
signal via a series of other electrodes. The specimen is scanned point by point to recreate 
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a 2D or 3D image of the sample. The second pinhole removes a lot of the emitted light 
lowering the signal intensity. Enhancement of the signal by increasing the intensity of the 
excitation wavelength has to be done cautiously, due to possible bleaching. Signal 
enhancement can also be achieved by adjusting the voltage of the detector or can be 
performed during image processing, for example by deconvolution of the image. A further 
enhancement of the resolution can be achieved through stochastical methods (STORM 
stochastic optical reconstruction microscopy) or by STED (stimulated emission depletion) 
imaging, where excitation of fluorophores surrounding the point of interest is depleted by 
the use of a second laser148, 149. 
 
 
Figure 7: Principle of confocal microscopy. Excitation light is reflected toward the sample by the 
dichroic mirror and is focused by the objective. Emitted light passes through the dichroic mirror and 
is collected by the detector. Out of focus light is not collected due to the presence of the pinhole.  
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For live cell imaging it is important to have reporters (fluorophores) for different readouts. 
Properties of fluorophores can be altered in response to changes in calcium, oxidative 
stress or pH enabling the study of changes of these molecules. Other fluorophores 
specifically label certain organelles or structures within the cell by an accumulation at the 
target structure. 
 
Live cell imaging is especially beneficial for studies on mitochondria in their native 
environment. Labelling of mitochondria with GFP allows the tracking of morphology and 
dynamics independent of the energization state of the mitochondria. ΔΨm is central to 
mitochondrial function, affecting processes such as ATP and ROS production, and Ca2+ 
and protein import. The positively charged, lipophilic, fluorescent dye tetramethyl rhodamine 
methyl ester (TMRM) accumulates in the matrix of mitochondria, which is negatively 
charged compared to the cytosol55. The degree of the accumulation is proportional to ΔΨm, 
when the dye is used in the linear range (for example 50 nM). Using TMRM in higher 
concentrations leads to self-quenching of the fluorophore, hence to a decrease in signal. 
The application of an uncoupler, such as FCCP, causes the mitochondria to depolarize and 
TMRM to leak into the cytosol; if TMRM is used in a linear range the mitochondrial signal 
will decrease, if the dye was used in a self-quenching concentration the signal in the 
mitochondria will increase. A change in ΔΨm can be caused by alterations of respiratory 
chain activity, the rate of ATP and the degree of proton leak. 
 
Mitochondrial targeted toxins often induce ROS150. Upon oxidative stress intracellular levels 
of hydrogen peroxide increase. Hydrogen peroxide can for example be measured with the 
transfectable sensor Premo Cellular Hydrogen Peroxide Sensor Orp1-roGFP. Orp1 forms 
disulfides upon reaction with hydrogen peroxide and can transduce the signal to the coupled 
roGFP, which leads to protonation of GFP and increases the 400 nm excitation spectra at 
the expense of the 488 nm excitation spectra, allowing a ratiometric readout of hydrogen 
peroxide levels151.  
Bodipy 581/591 undecanoic acid can be used to detect lipid peroxidation. The oxidation of 
the polyunsaturated butadienyl portion of the dye results in a shift of the fluorescence 
emission peak from 590 nm to 510 nm152. The shift can be determined by measuring the 
ratio between the emission at both wavelength before and after the treatment. 
 
A variety of Ca2+-sensitive probes are available that can be loaded into cells and respond 
to Ca2+ by increasing their fluorescence153. Some of the sensors are known to accumulate 
in mitochondria (Rhod-2 and XRhod) and can be used to track Ca2+ levels inside the 
organelles154, 155. To ensure loading into the cells, most Ca2+ probes are prepared as an AM-
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ester, which masks charged groups and enhances the lipid solubility. Intracellular esterases 
will release the hydrophilic fluorescent indicator to bind Ca2+ for the detection. 
 
The fluorescent properties of NADH in ultraviolet light and of FAD2+ upon excitation with 
450 nm can be used to determine the redox state of the cell156. The oxidized form of NADH 
and the reduced form of FAD2+ are not fluorescent. Measuring the relative intensity of the 
fluorescent signal arising from NADH and FAD2+ has been suggested to allow the deduction 
of the relative redox states of the two substrate pools55. Inhibition of respiratory chain, for 
example, would push the substrate pools into a reduced state, since they would no longer 
be oxidized by the respiratory chain complexes. The autofluorescence signal from NADH 
would be maximal, whilst the FAD2+ signal being minimal. On the other hand uncoupling of 
respiratory chain with FCCP has the opposite effect since the substrates would be in the 
oxidized state. One caveat to the above is that this is not purely a readout of respiratory 
chain function, since the oxidized forms NAD+ and FAD2+ are continuously reduced in the 
citric acid cycle56. 
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1.6.2 Multiphoton microscopy 
Although confocal microscopy is a powerful tool to study the physiological process in cells, 
the technique reaches its limit in more complex structures such as slices of an organ or the 
whole organ. For single photon excitation of fluorophores, the wavelength used lies in the 
ultra violet to visible range. The short wavelength light does not penetrate tissue well and 
undergoes more scattering compared to longer wavelength (infrared) light. Additionally, the 
illumination along the z-axis causes even more problems, namely bleaching than in thin cell 
sections as described in 1.6.1. 
 
 
Figure 8: Differences between confocal and multiphoton microscopy. (A) One photon of a certain 
wavelength excites the fluorophore before light with a longer wavelength is emitted to return to the 
ground state with one photon excitation. Alternatively, fluorophores can get excited by 2 or more 
photons of longer wavelength arriving at the same time. (B) Linear illumination in confocal microscopy 
results in a cone of light around the focal point, whereas nonlinear illumination as performed in 
multiphoton microscopy does not induce excitation of the fluorophores in other planes157. (Green 
represents excited fluorophores in this scheme)  
 
These disadvantages led to the development of multiphoton microscopy. The phenomenon 
of two photon absorption was first described in 1931 by Göppert-Mayer158. Two photons 
that arrive almost simultaneously (within 0.5 fs) at a molecule, can combine their energy to 
bring a fluorophore into an excited state, which then proceeds along the normal 
fluorescence to return to ground state157, 159 (Figure 8 A). Similar multiple photons can 
combine to cause excitation. Since the arriving photon combine their energy, the 
wavelength of each photon is half the wavelength that is needed for a single photon 
excitation. In order for two photons to arrive at the fluorophore at the same time, the 
excitation light has to be concentrated in space and time. Focusing on one spot (space) can 
be achieved by using objectives with high numerical aperture; concentrating the signal in 
time requires a laser emitting ultrashort (less than a picosecond long) pulses with high 
intensity. The probability of two photons concurrently appearing outside of the focal point is 
very low. Therefore, excitation occurs in a single spot unlike the double cone illumination in 
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confocal imaging (Figure 8 B). This reduces the risk of phototoxicity. Additionally, the signal 
strength is increased compared to confocal imaging since no pinhole is needed. 
Furthermore, the use of higher wavelength light increases penetration depth by reducing 
scattering from the tissue160. 
 
Multiphoton microscopy is therefore an ideal tool to investigate cellular physiology in 
complex tissues and even enables intravital imaging in a subcellular resolution. This 
technique enables the visualization of mitochondrial morphology and function in the living 
animal, as shown recently by our group160, and was therefore, in combination with live cell 
imaging and multiphoton microscopy of kidney slices161, the ideal tool for investigating the 
mechanism of DFX induced kidney toxicity. 
 
1.7 Aims of this work 
1. To investigate whether the nephrotoxicity of DFX is due to a toxic effect on 
mitochondria, by describing the effect of DFX on mitochondrial morphology and 
function in PT cells. 
2. To determine whether DFX toxicity is due to iron chelation or an off-target effect. 
3. To establish whether DFX toxicity is specifically localized to the PT in an 
experimental mouse model, and if so, whether uptake of the drug by endocytosis 
might explain this. 
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Technical equipment 
Table 7. List of equipment and providers/manufacturers.  
Equipment Provider/Manufacturer 
Seahorse XFp Analyzer Agilent 
Synergy 2, Multidetection reader Biotek 
EM HPM 100, high pressure freezer Leica 
Ultracut E, Ultramicrotome Reichert 
SP8 inverse STED 3X, microscope Leica 
SR GSD 3D microscope Leica 
Microm HM 650 F, Vibratome Thermo Scientific 
Fluoview 1000 multiphoton microscope Olympus 
Libra S70 double beam spectrophotometer Biochrom 
Mini-Extruder, 0.1 µm pore size nucleopore polycarbonate membrane Avanti 
 
2.1.2 Chemicals and reagents 
Table 8. List of chemicals and reagents including supplier.  
Chemical/Reagent Provider 
Acutase Thermo Fisher Scientific 
Amplex Red Hydrogen Peroxide/Peroxidase Assay Kit Thermo Fisher Scientific 
Antimycin A Sigma Aldrich 
Ascorbate Sigma Aldrich 
Bovine Serum Albumin Sigma Aldrich 
Cadmium Sigma Aldrich 
Cardiolipin Sigma Aldrich 
Catalase Sigma Aldrich 
Cisplatin Sigma Aldrich 
Colchicine Sigma Aldrich 
Cyanide Sigma Aldrich 
Cyclosporine A Sigma Aldrich 
Cytochalasin D Sigma Aldrich 
Cytochrome C Sigma Aldrich 
Deferasirox Selleckchem and Biochempartner 
Deferiprone Sigma Aldrich 
Deferoxamine Sigma Aldrich 
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Chemical/Reagent Provider 
Diclofenac Tocris Biosciences 
Dimethylsulfoxide Sigma Aldrich 
DMEM/F-12 Thermo Fisher Scientific 
Dodecyltriphenylphosphoniumbromide Sigma Aldrich 
Fetal bovine serum (FBS) Thermo Fisher Scientific 
FCCP (Carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone) 
Sigma Aldrich 
Glacial Acid Sigma Aldrich 
Hydrazinobenzoic Acid Sigma Aldrich 
Hydrogen Peroxide Sigma Aldrich 
Iron (III) Ammonium Citrate Sigma Aldrich 
Loctite 406 Distrelec 
MitoQ MedKoo 
Neutral Red Sigma Aldrich 
Oligomycin Sigma Aldrich 
Paraformaldehyde Sigma Aldrich 
Pluronic Sigma Aldrich 
RAP Molecular Innovations 
Salicylic Acid Sigma Aldrich 
Simvastatin Sigma Aldrich 
SS-31 China Peptides 
TMPD Sigma Aldrich 
Triton-X 100 Thermo Fisher Scientific 
Trypan blue Sigma Aldrich, 0.4 % diluted to 0.05 % in 
PBS 
Tween Thermo Fisher Scientific 
Valinomycin Sigma Aldrich 
Verapamil Sigma Aldrich 
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2.1.3 Dyes 
Table 9: Dyes for live cell imaging 
 
  
Dye Excitation/Emissio
n 
Concentration Provider 
Albumin-AF488 488/525 600 µg/120 µl Thermo Fisher Scientific 
Bacmam Mito GFP 488/508 5 particles per cell 
+ enhancer 
Thermo Fisher Scientific 
Bodipy 581/591 C11 510+580/581+591 2 µM Thermo Fisher Scientific 
Calcein 495/515 50 mM Sigma Aldrich 
Calcein AM 495/515 250 nM with 2.5 
mM Probenecid 
Thermo Fisher Scientific 
ER tracker blue white 405/555 1 µM Thermo Fisher Scientific 
Mitotracker deep red 644/660 200 nM Thermo Fisher Scientific 
Mitotracker green 488/510 200 nM Thermo Fisher Scientific 
Premo Cellular Hydrogen 
Peroxide Sensor 
400/488+515 80 particles per cell 
+ enhancer 
Thermo Fisher Scientific 
Rhodamine 123 505/530 50 nM Thermo Fisher Scientific 
SiR tubulin 650/675 2 µM with 10 µM 
verapamil 
Spirochrome 
Tetramethylrhodamine 
(TMRM) 
555/580 50 nM Thermo Fisher Scientific 
XRhod 580/600 2 µM Thermo Fisher Scientific 
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2.1.4 Buffers and solutions 
Table 10. Compositions of buffers and solutions 
 Composition  
PBS 136.89 mM NaCl, 2.68 mM KCl, 10.14 mM Na2HPO4, 1.76 mM 
KH2PO4, adjusted to pH 7.4 
Cell buffer 138 mM NaCL, 5.6 mM KCl, 1.2 mM NaH2PO4, 2.6 mM CaCl2, 
1.2 mM MgCl2, 10 mM glucose, 4.2 mM NaHCO3, 10 mM 
HEPES, adjusted to pH 7.4 
Kidney slice buffer 118 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.8 mM CaCl2, 1.44 
MgSO4, 5 mM glucose, 10 mM NaHCO3, 10 mM HEPES, 5 mM 
pyruvate, 2.5 mM sodium butyrate, 2.5 mM sodium lactate, 
adjusted to pH 7.4 and gassed with carbogen (95 % O2/ 5 % 
CO2) 
Liposome buffer 100 mM KCl, 10 mM Tris, 10 mM MES 
PHEMO buffer 68 mM PIPES, 25 mM HEPES, 15 mM EGTA disodium, 3 mM 
MgCl2,adjusted to pH 6.8 
0.1 M phosphate buffer 19 mM NaH2PO4, 81 mM Na2HPO4, 230 µM CaCl2, adjusted to 
300 mOsm and pH 7.4 
 
2.1.5 Antibodies 
Table 11. List of monoclonal (m) or polyclonal (p) primary and secondary antibodies used for 
immunofluorescence (IF)  
Antibody 
(against) 
Fluorophore Host m/p  Dilution  
 
Provider 
TOM-20 --  rabbit p 1:150, 1:125 
for STED  
Santa-Cruz, sc11415 
Cytochome C -- mouse m 1:50 Biolegend, 6H2.B4 
rabbit Alexa 488 donkey p 1:500 Jackson Immuno Research 
rabbit Abberior 
Star 635 
goat p 1:200 Abberior GmbH 
rabbit Alexa 555 goat p 1:200 Thermo Fisher Scientific 
mouse Atto 594 goat p 1:200 Sigma Aldrich 
 
2.1.6 Software 
Table 12. List of software used for analysis, visualization and interpretation of data. 
Software Provider 
Adobe Illustrator Adobe Systems 
Fiji Open Source 
Graph Pad Prism GraphPad Software, Inc. 
Huygens Professional deconvolution Scientific Volume Imaging 
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Software Provider 
Ilastik Open Source 
Leica LAS AF Lite Leica 
Mahematica Wolfram Research 
 
2.1.7 Statistical analysis 
All statistical analysis was performed using Graph Pad Prism. Significance of differences 
between control and treatment was tested with a 1-way ANOVA, posthoc Dunnett’s multiple 
comparison test. All experiments were at least performed in triplicates. 
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2.2 In vitro studies 
2.2.1 Cell lines 
OK cells, a proximal tubular cell line from opossum kidney, were a kind gift from the group 
of Prof. Olivier Devuyst (Institute of Physiology, University of Zurich). Currently, OK cells 
remain the preferred model for the S1 segment, as it mostly resembles ion transport 
functions from the PT, expresses megalin, has a robust apical endocytosis and is well 
differentiated162. The OK cells were grown in DMEM/F-12 medium supplemented with 10 % 
FBS under standard tissue culture conditions (37°C, 5 % CO2). Splitting took place once 
per week and was performed as follows: after removal of medium cells were washed once 
with PBS (37°C), before 1 ml of accutase was added and cells were allowed to detach for 
10 min at 37°C. The enzymatic reaction of acutase was stopped by the addition of 10 ml of 
warm culture medium with 10 % FBS, before the cell suspension was centrifuged at 200g 
for 5 min. The medium was removed, and the cell-pellet was resuspended in 6 ml warm 
culture medium. For cell counting 20 µl of cell suspension were mixed with 60 µl 0.05 % 
trypan blue and added in a hemocytometer. Only viable cells did not take up trypan blue 
due to an intact cell membrane were counted. The cell number was calculated using the 
following formula: viable cells per ml suspension = number of viable cells in one big square 
x 4 (dilution factor) x 104. Appropriate cell concentrations for seeding into different culture 
formats (Table 13) were gained by dilution with culture medium. Cells were used from P 20 
to P35. 
Table 13: Cell densities of OK cells 
Format Cell density per well Volume per well 
75 cm2 flask 3.5 x 105 10 ml 
25 cm2 flask 1 x 105 5 ml 
12 well plate 1.8 x 105 1 ml 
4 well imaging chamber 1.4 x 105 500 µl 
96 well plate 1 x 104 100 µl 
Seahorse plate 5 x 103 70 µl 
 
To label mitochondria with GFP, cells were incubated for 2 hours with CellLight 
Mitochondria-GFP BacMam 2.0 (5 particles per cell) and BacMam enhancer (both Thermo 
Fisher Scientific) one day prior to experiment. For the detection of intracellular H2O2, cells 
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were exposed to Premo Cellular Hydrogen Peroxide Sensor Orp1-roGFP (80 particles per 
cell) and BacMam enhancer 24 hours before microscopic analysis. 
For the analysis of cytochrome c release by immunostaining, a different cell line, COS-7, 
had to be used due to incompatibility of the antibody with OK cells. COS-7 cells were kindly 
provided and grown by the Centre for Microscopy and Image Analysis of the University of 
Zurich. They were cultivated under standard conditions in DMEM medium containing 4.5 g/l 
D-glucose, 10% FBS and 1% L-glutamine. 
 
2.2.2 Cell viability assay (Neutral Red Assay) 
Cell viability in response to DFX treatment was assessed using the Neutral Red Assay142. 
The assay is based on the ability of the weakly cationic dye neutral red to penetrate cell 
membranes by passive non-ionic diffusion. The dye accumulates in lysosomes, where it 
binds to anionic and/or phosphate groups by electrostatic hydrophobic bonds. Due to the 
acidic pH in lysosomes neutral red changes its net charge and can no longer leave the 
lysosome. The pH in lysosomes is maintained by the proton gradient, which is generated 
by the proton pumping V-type ATPase. The enrichment of neutral red in the lysosomes 
therefore reflects cellular ATP levels and cell viability. 
For the assay OK cells were seeded in 96 well plates one day prior to treatment with DFX 
for 24 h. Upon the start of the assay, cells were incubated for 2 h with neutral red medium 
at 37°C to allow the dye to be enriched in lysosomes. Excess dye, that did not change its 
net charge, was removed by washing with PBS. To measure the dye that was bound in the 
lysosomes, cells were lysed with 50 % ethanol, 49 % water and 1 % glacial acid, before 
optical density was measured at 540 nm using a multi detection reader. Measured values 
were normalized to control cells after the blank was subtracted. 
 
2.2.3 Confocal live cell imaging 
For confocal live cell imaging OK cells were seeded one day prior to the experiment on 
poly-L-lysine coated coverglasses (ø 18 mm, thickness 1) or in a CELLview dish with 4 wells 
and grown to a confluence of 70-90 %. For the coating coverglasses were placed into a 12 
well plate (one per well), sterilized by incubation in 70 % ethanol for at least 5 min before 
0.01 % poly-L-lysine was added and incubated at RT for at least 1 h. Excess poly-L-lysine 
was removed by washing 3 times with water before cells were plated. 
For staining, cells were incubated at 37°C for at least 1 h in cell buffer (Table 10) containing 
the appropriate dye concentration (Table 9), before being mounted in a ludin chamber 
(mounting not necessary if cells were grown in CELLview imaging dish) and placed onto 
the stage of the microscope with controlled environmental conditions (37°C). Confocal 
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imaging was performed on a Leica SP8 inverse STED 3X equipped with a white light laser 
(470-670 nm), a diode laser 405 nm and a HC PL APLO STED WHITE 100x/1.4 objective. 
When new dyes or dye combinations were used for the first time, staining was monitored 
on stage to evaluate how long it takes to reach a stable baseline of signal. Laser intensities 
were tested on control cells to determine the intensity that does not induce damage but 
ensures sufficient signal to noise ratio. 
Acute treatment with drugs was performed by addition of 2x concentrated drug solution into 
the live cell imaging chamber using a glass pipette, so as not to disturb the recording of the 
image series.   
 
2.2.4 Immunofluorescence for confocal, STED and STORM imaging 
Immunofluorescence staining was performed for confocal, STED and STORM, both super 
resolution microscopy methods. 
Immunofluorescence is based on the detection of the protein of interest by its interaction 
with a specific antibody, the so called primary antibody. Binding of the polyclonal, 
fluorescently labelled secondary antibody to the primary antibody multiplies the signal and 
allows the localization of the protein of interest using fluorescence microscopy (all 
antibodies and their dilutions are listed in Table 11). STED and STORM microscopy both 
allow imaging in a resolution beyond the defraction limit148, 149. This is achieved in STED 
microscopy by depleting out of focus fluorescence that occurs by excitation of the 
fluorophores. The so-called depletion laser is donut shaped surrounding the excitation laser 
and allows an increased resolution. In STORM a strong laser pushes the fluorophores into 
a dark state from which single molecules may return into an emissive state. This allows the 
localization of single fluorophores. During long measurements (almost) every molecule will 
once return into the emissive state, allowing a reconstruction of the actual localization of all 
fluorophores in one image. 
 
OK cells or - for STED imaging of cytochrome c - COS-7 cells, were grown as described in 
chapter 2.2.3 on coated coverglasses. After treatment with the control medium and DFX, 
the remaining medium was removed by washing it with warm PBS. For confocal and STED 
imaging cells were fixed at RT for 10 min with 3 % paraformaldehyde in PBS (30 g/l, 
depolymerized to formalin after heating), which crosslinks proteins, primarily lysine 
residues. Permeabilization with 0.1 % TritonX-100 for 5 min ensured that the primary 
antibody can reach the target protein. After washing three times with PBS, nonspecific 
binding of the primary antibody was prevented by blocking for 30 min at RT with 1 % BSA.  
For confocal imaging, samples were additionally blocked with donkey serum diluted 1:10 in 
the BSA solution. Afterwards, cells were incubated with the primary antibody TOM-20 
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(rabbit, polyclonal) diluted 1:150 in the 1 % BSA solution overnight. Excess antibody was 
removed in three washing cycles using PBS, before cells were incubated with the secondary 
antibody (donkey anti rabbit conjugated with Alexa 488) diluted 1:500 in 1 % BSA solution 
for 2 h at RT. After washing 3 times with PBS, coverglasses were mounted on glass slides 
using DAKO glycergel mounting medium as embedding medium. Once the mounting 
medium dried the edges of the coverglass were sealed with clear nail polish. 
Differences of the staining for confocal imaging and STED microscopy were the dilution of 
antibodies – primary: 1:125 for TOM-20 and 1:50 for cytochrome C (mouse, monoclonal); 
secondary: 1:200 goat anti rabbit coupled to Abberior Star 635 and 1:200 goat anti mouse 
coupled to Atto 594 – and the mounting medium ProLong Diamond antifade mountant. 
For STORM imaging it was important to use secondary antibodies conjugated with dyes 
that demonstrate a better “blinking” behavior (switch from dark to emitting state) and that 
the generation of radicals due to the long imaging duration is restrained. After the treatment 
OK cells were fixed using 37°C PHEMO buffer supplemented with 3.7% formaldehyde and 
0.05 % glutaraldehyde for 10 min at RT. After washing with PBS, cells were permeabilized 
with 0.1 % TritonX-100 for 1 min, washed again with PBS and blocked with 1 % BSA for 30 
min at RT. Primary (1:150 TOM-20) and secondary antibody (1:200, goat anti rabbit 
conjugated with Alexa 555) were both incubated for 1 h at RT, with three washes using PBS 
in between. To minimize radical generation during imaging, cells were mounted in 
vectashield/50mM Tris in 87 % glycerol (1/2.15) and sealed with 2 component Twinsil 22. 
Confocal and gated STED imaging of the fixed samples was performed on a Leica SP8 
inverse STED 3X using the HC PL APO STED WHITE 100x/1.4 objective and white light 
laser as described in section 2.2.3. For STED imaging, in addition to the excitation of the 
fluorophores at 585 nm (Atto 594) and 635 nm (Abberior Star 635), the depletion laser was 
used at full power and a wavelength of 775 nm. 
3D STORM imaging was performed on a Leica SR GSD 3D microscope using a HCX PL 
APO (GSD/TIRF) 160x/1.43 objective. Excitation was performed using a 642 nm laser and 
a 710/100 bandpass was used for the emission. 
 
2.2.5 Image analysis 
Data from confocal and STED imaging was deconvolved using Huygens Professional 
software. Image processing for all microscopy data was done in FIJI and Imaris 8.3. 3-D 
STORM images were processed using FIJI and the ThunderSTORM plugin163. To 
investigate the effect of DFX on mitochondrial energization, the GFP-mitochondrial channel 
of the image time series was segmented, and the resulting mitochondrial localization 
tracked over time using supervised machine learning (Ilastik: Interactive learning and 
segmentation toolkit, http://doi.org/10.1109/ISBI.2011.5872394). Using the tracking results, 
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intensities of both the GFP and the TMRM channel were extracted using FIJI. The obtained 
fluorescence intensity data was combined to trajectories and further analyzed and 
visualized using Mathematica. The bimodal distribution of the TMRM signal allowed the 
calculation of a polarization survival probability using fixed thresholds. For the long term 
dynamic effect the same approach was used, and 36 randomly acquired images containing 
mitochondrial signals from multiple cells were analyzed per time point. 
 
2.2.6 Respirometry 
For the evaluation of the effect of DFX on oxidative phosphorylation, oxygen consumption 
was measured using a Seahorse XFp analyzer. The measurement is based on a 
fluorophore sensitive for oxygen that is integrated into a cartridge, which is lowered down 
to the cells creating a transient chamber (distance fluorophore to cells 200 µm) that allows 
localized measurements of the decay of oxygen concentration. 
One day prior to the experiment, cartridges were hydrated with XF calibrant (200 µl per well, 
400 µl per moat, incubation at 37°C without CO2 until use) and cells were plated in Seahorse 
XFp 8 well culture plates, whereby one well was not filled with cells to serve as a blank in 
the assay. One hour before analysis cells were incubated without CO2 in cell buffer (Table 
10, 200 µl per well). In the meantime, cartridges were filled with the stock solutions of drugs 
dissolved in cell buffer according to Table 14. 
Table 14: Scheme for cartridge loading for respirometry 
 Port Stock Concentration 
in port 
Injection 
volume 
Concentration 
on cells 
DFX A 100 mM 2.2 mM 20 µl 200 µM 
Ascorbate/TMPD B 800/200 mM 34/8.5 mM  13.75 µl 2/0.5 mM 
Cyanide C 500 mM 9 mM  13.75 µl 500 µM 
Complex III 
blocking  
Port Stock Concentration 
in port 
Injection 
volume 
Concentration 
on cells 
Antimycin A 100 mM 52.5 µM 10 µl 2.5 µM 
DFX B 100 mM 2.3 mM 20 µl 200 µM 
Cyanide C 500 mM 12 mM 10 µl 500 µM 
 
After calibration of the cartridge in the Seahorse XFp (automated protocol from 
manufacturer) the cell plate was inserted into the machine. After the automatic equilibration, 
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baseline was measured in 3 cycles, each consisting of 2 min mixing and 2 min measuring. 
The same measurement procedure was performed after each injection of a drug. The 
values were analyzed using the software Wave and were normalized to the mean 
measurements of the baseline using Excel and Graph Pad. 
 
2.2.7 Electron microscopy of OK cells 
For transmission electron microscopy OK cells were grown in a 12 well plate on carbon 
coated (5-20 nm, for better attachment of the cells) 6 mm sapphire discs. Before the 
specimen carrier was assembled, a loading station was created by placing the middle plate 
“bridge-like” over two spacers (for example tape) on top of a petri dish. The slight elevation 
of the middle plate prevents capillary forces from drawing out medium from the cells. The 6 
mm sapphire disc with the treated cells was placed on the edge of the middle plate hole 
with the cells facing up and covered with a 6 mm aluminium specimen carrier type A, wetted 
with hexadecane, leaving a gap of 100 µm between disc and carrier. To fill the remaining 
gap a 200 µm spacer ring was placed on top of the aluminium carrier (Figure 9). After the 
assembly in the middle plate cells were immediately high pressure frozen using a stream of 
liquid nitrogen running through the lower and upper half of the cylinder with a pressure of 
2100 bar, ensuring high cooling rates and freezing of the sample within 2.5 s (Figure 9). 
After freezing the specimen the carrier was disassembled and the sapphire disc was kept 
in liquid nitrogen until freeze substitution was performed.  
 
Figure 9: Specimen carrier assembly for high pressure freezing of cells grown on carbon coated 6 
mm sapphire discs. During high pressure freezing a stream of liquid nitrogen at 2100 bar ensures 
high cooling rates on the sample assembled in the middle plate. 
 
For the embedding in resin, water in the sample had to be replaced. Freeze substitution 
was carried out in water free acetone with 1 % OsO4 (contrast enhancement) for 8 h at -
90°C, 7 h at -60°C, 5h at -30°C and 1 h at 0°C with transition gradients of 30°C per hour. 
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Afterwards, samples were rinsed twice in water free acetone, before they were stained for 
1 h in 1 % uranyl acetate (stock 20 % in methanol) in acetone at 4°C and rinsed again twice 
with water free acetone. For the embedding in the resin, samples were first incubated 
overnight in 66 % Epon/Araldite in acetone, then in 100 % Epon/Araldite for 1 h at RT, 
before the resin was polymerized for 20 h at 60°C.  
70 nm thick sections were cut on an Ultramicrotome and images were acquired with an FEI 
CM 100 equipped with a Gatan Orius 1000 camera. 
 
2.2.8 Calcein leakage in Liposomes 
To evaluate if DFX creates pores in the inner mitochondrial membrane, liposomes with a 
lipid composition resembling the inner mitochondrial membrane were produced. The 
liposomes contained the dye calcein in a concentration of 50 mM. At this high concentration 
calcein is self-quenching, meaning less fluorescent. Upon rupture, calcein is released and 
diluted to a non-quenching concentration resulting in an increase in fluorescence, which is 
the readout for the assay (Figure 10)164. 
 
Figure 10: Principle of calcein leakage in liposomes. Liposomes, resembling the inner mitochondrial 
membrane, are filled with a self-quenching concentration. Upon rupture, calcein is released and 
diluted to a concentration where no self-quenching occurs inducing a rise in fluorescent signal.  
 
At first the lipid mixture of 4 mg phosphatidylcholine and 1 mg cardiolipin was dissolved in 
chloroform and evaporated in a stream of nitrogen. The lipid mixture was then hydrated (2 
% solution of lipids in buffer) with 1:2 diluted liposome buffer containing 50 mM calcein.  
The calcein concentration had been determined prior to use by measuring the absorption 
at 495 nm compared to buffer without calcein as reference using a spectrophotometer. The 
concentration was calculated according to the law of Lambert-Beer using the equation c = 
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A/ε*l with c = concentration of calcein, A = measured absorption at 495 nm, ε = extinction 
coefficient of calcein 77000 cm-1 M-1 and l = length of used cuvette (here 1 cm). 
After vortexing and several freeze thaw cycles the lipid dye mixture was extruded through 
a 0.1-µm pore size Nuclepore polycarbonate membrane using a mini extruder, resulting in 
liposomes filled with calcein. Excess dye was removed by dialyzing against liposomes 
buffer for 48 h at 4°C with slow stirring using Slide-A-Lyzer MINI 7K. Dialysis buffer was 
changed 6 times. 
For the assay liposomes were diluted in liposome buffer to a concentration of 500 ng/ml. 
Fluorescence was recorded at 508-548 nm (excitation 465-505 nm) every minute using a 
Synergy multi detection reader. Before the addition of drugs (experimental conditions: 
buffer, DFX 200 µM and 1 mM, DTPP 200 µM, the detergent Triton-X 100 served as positive 
control and DMSO as solvent control) a baseline value (only liposomes in the well) was 
measured for 5 min. 
 
2.2.9 Amplex Red Assay 
Upon oxidative stress cytochrome c can act as a peroxidase inducing lipid peroxidation of 
cardiolipin, which leads to a disruption of cristae165. The mitochondrial targeted antioxidant 
SS-31 is thought to be protective during ischemia due to the protection of peroxidation of 
cardiolipin and due to its antioxidant properties166. As iron is crucial for the peroxidase 
activity of cytochrome c, DFX might provoke an increased activity of the peroxidase leading 
to the disruption of mitochondria. 
To measure the activity of cytochrome c peroxidase an Amplex Red assay can be used. In 
the presence of peroxidase, the Amplex Red reagent reacts with hydrogen peroxide in a 
1:1 stoichiometry to produce the red-fluorescent product resorufin167. The increase in 
fluorescence can be detected and is the readout for peroxidase activity. It was taken into 
account that cardiolipin enhances peroxidase activity, and that a decrease in peroxidase 
activity could also be due to an interaction with cardiolipin168. 
In 50 µl of 50 µM sodium phosphate (pH 7.4) cytochrome c (800 nM), cardiolipin (60 µM) 
and DFX (0.8 – 400 µM) or control were mixed and added into a well of a black 96 well 
plate, similar to previously reported cytochrome c peroxidase activity assays164, 166, 169. To 
start the reaction 50 µl of the mix of Amplex Red (40 µM) and hydrogen peroxide (50 µM) 
in 50 µM sodium phosphate were added. Immediately after addition of the dye and hydrogen 
peroxide fluorescence signal was read every 20 s for 10 min using a 540/20 filter for the 
excitation and 620/40 filter for emission on the Synergy 2 multi detection reader. The final 
concentrations of the single substrates in one well were 400 nM cytochrome c, 30 µM 
cardiolipin, 20 µM Amplex Red, 25 µM hydrogen peroxide and 0.4 – 200 µM DFX. 
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2.3 Animal studies 
All experiments were performed on C57BL/6JRj mice from Janvier aged between 8 to 13 
weeks. Animals were housed under standard conditions with standard chow. All animal 
experiments were approved by the Zurich Cantonal Veterinary Office (Licence 021/15). 
 
2.3.1 Cortical kidney slices 
After the evaluation of the effects of DFX in OK cells, the effect on kidney tissue was 
investigated using multiphoton microscopy. Mice were anaesthetized with intraperitoneal 
injection of Ketamine and Xylazine with a dose of 0.065 and 0.01 g/kg bodyweight, 
respectively, before kidneys were externalized. After the removal of the capsule one pole 
of the kidney was mounted onto the sample holder of the vibratome using a drop of glue 
(Loctite 406). To accelerate hardening of the glue one ml of kidney slice buffer was added, 
before the sample holder was placed into the vibratome, where it was cut into 250 µm thick 
sections. Until use the kidney slices were kept at 4°C in kidney slice buffer (Table 10) 
gassed with carbogen (95 % O2/5 % CO2). For staining with TMRM, kidney slices were 
incubated in 50 nM TMRM for 1 hour at RT prior to imaging. Kidney slices were then 
carefully mounted into a heated tissue slice chamber with gassed slice buffer for imaging. 
Imaging was performed with an Olympus Fluoview 1000 MPE equipped with a XPlan N 
25x/1.05 objective, coupled to an ultrafast Ti:Sapphire laser system. For the detection of 
NAD(P)H the laser was tuned to 720 nm and for TMRM to 850 nm. Drugs were added 
directly into the chamber using a glass pipette. 
 
2.3.2 In vivo treatment of mice with DFX 
For the in vivo study of the effect of DFX on the PT, animals received a single intraperitoneal 
injection of 100 mg/kg bodyweight of DFX daily dissolved in saline and 0.16 % Tween for 
ten days. Control animals were injected with saline and Tween only. No change in behavior 
was detectable during the treatment period. 
 
2.3.2.1 In vivo imaging 
Intravital imaging was performed as described previously160. Mice were anaesthetized with 
2.5 % isoflurane in 100 ml/min oxygen. The internal jugular vein was cannulated for the 
application of dyes and the kidney was externalized. Animals were then placed on a 
temperature-controlled holder, that was designed to dampen transmission of breathing 
movement to the kidney during image acquirement, and the kidney was fixed onto the holder 
using agarose (Figure 11). The temperature of the animal was monitored throughout the 
experiment. 
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Figure 11: Schematic drawing of mounting the mouse on the multiphoton microscope for in vivo 
imaging. After cannulation of the jugular vein for dye application and the exteriorizing of the kidney, 
the mouse is placed onto the temperature-controlled holder. The kidney is stabilized by the addition 
of agarose and imaging is performed from below through a coverglass. 
 
Imaging was performed on a custom-built multiphoton microscope operating in inverted 
mode equipped with a broadband (680 – 1300 nm) tunable laser (Insight DS Dual, 
Spectreaphysics) and a XPlan N 25x/1.05 water immersion objective. 
To study mitochondrial morphology 30 µg of TMRM in 120 µl 0.9% saline were injected, 
while for investigating protein uptake 600 µg of Alexa 488 labelled albumin was injected in 
120 µl 0.9% saline. Both dyes were excited at 800 nm and emission was detected using 
gallium-arsenide-phosphide (GaAsP) detectors with bandpass filters 525/50 and 605/50. 
For controlling image acquisition, the ScanImage 3.8 software package was used. 
 
2.3.2.2 Electron microscopy of kidney tissue 
To further evaluate mitochondrial morphology in mice treated with DFX, control and DFX 
exposed mice were anesthetized using isoflurane, before they were perfused via the 
abdominal aorta first with 30-50 ml 0.1 M phosphate buffer (Table 10) to remove blood 
before kidneys were fixed with 50 ml 3 % paraformaldehyde in 0.1 M phosphate buffer. After 
5 min of fixation the animal was perfused with around 30 ml 0.1 M phosphate buffer, before 
kidneys were externalized. The capsule was removed, before each kidney was divided into 
6 pieces by transverse sections. The sections (3 per 2 ml tube) were stored in 2.5 % 
glutaraldehyde in 0.1 M phosphate buffer at 4°C until further processing. 
The cortex was sectioned into 1x1x1 mm pieces in 0.1 M sodium cacodylate buffer and 
pieces were transferred into a 2 ml tube and washed 3 times with 0.1 M cacodylate buffer. 
The first step of contrast enhancement was performed by incubating the tissue in 1 % OsO4 
in 0.1 M cacodylate buffer for 1 h on ice. After washing three times with dH2O, kidney tissue 
was incubated in 1% uranyl acetate in 0.1 M cacodylate buffer on ice for 1 h in the dark to 
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further enhance the contrast. Remaining uranyl acetate was removed by washing three 
times with dH2O. Dehydration of the samples was performed by progressively increasing 
the ethanol content of the solution the samples were kept in. Tissue was incubated first in 
70%, then in 80% ethanol for 20 min each, before ethanol was increased to 96% for 25 min. 
Following incubations in 100% water free ethanol (2 x 15 min) and 30 min in propylene 
oxide, embedding was started in 50% Epon/Araldite in propylene oxide two times for 1 h 
each. Samples were then incubated two times in 100% Epon/Araldite in propylene oxide for 
50 min each, before single tissue pieces were transferred into molds and filled with 100% 
Epon/Araldite. Samples were polymerized for 24 h at 60°C. 
Further processing and imaging was performed as described in chapter 2.2.7. 
 
Results  
48 
3 RESULTS 
3.1 Phenotyping the effect of DFX on proximal tubular cells 
3.1.1 DFX induces acute mitochondrial swelling in proximal tubular cells 
At the beginning of the study it was necessary to evaluate whether DFX is effective in 
inducing damage to our in vitro modelling system of the PT, the OK cells. For the first 
estimation of an effective concentration of DFX, OK cells were treated with DFX in various 
concentrations, before cell viability was estimated using neutral red assay. This assay is 
based on the ability of the cell to maintain pH gradients via the production of ATP, which 
reflects the cell viability. We found a decrease of cell viability after 24 h of DFX treatment in 
a concentration dependent manner with a half maximal inhibitory concentration IC50 of 246 
µM (Figure 12). To further investigate the effects of DFX on PT cells, we chose a 
concentration of 200 µM that does not cause major cell death in acute treatment. In humans, 
therapeutic plasma concentrations of DFX ranged from 100-200 µM after daily dosing of 
20-30 mg/kg130.  
 
Figure 12: Cell viability measured by Neutral Red Assay in OK cells after 24 h treatment with DFX 
normalized to control treatment. The IC50 was calculated using log (inhibitor) vs. normalized response 
variable slope analysis at 246 µM. 
 
The next step was to investigate whether DFX induces its nephrotoxicity (Fanconi 
syndrome) by interfering with mitochondrial structure and function. For this we used live 
imaging of OK cells stained with the mitochondrial targeted dye Mitotracker deep red. Upon 
treatment with 200 µM DFX mitochondria rapidly started to swell (5 min), eventually leading 
to a phenotype of rounded, swollen mitochondria (Figure 13). This was indicative of DFX 
inducing kidney toxicity via mitochondrial dysfunction. 
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Figure 13: Acute swelling of mitochondria in OK cells upon treatment with 200 µM DFX. Cells had 
been stained with Mitotracker deep red. Scale = 10 µm. 
 
To investigate mitochondrial energization, OK cells were stained with the mitochondrial 
membrane potential dependent dye TMRM. This cationic dye accumulates in respiring, and 
therefore negatively charged, mitochondria. Upon DFX treatment for 30 min, a 
mitochondrial swelling occurred without a loss of potential (Figure 14). Treatment with 
solvent control did not induce swelling of mitochondria or a change in potential. In addition, 
we measured whether changes in density of the mitochondria occur using phase contrast 
imaging. In control cells mitochondria were hardly distinguishable in the phase contrast, 
whereas the swollen mitochondria of DFX treated cells appear lighter, signifying a lower 
matrix density (Figure 14).   
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Figure 14: Treatment with 200 µM DFX for 30 min induces mitochondrial swelling without loss of 
mitochondrial membrane potential detected by staining with TMRM (left). No swelling occurred with 
control treatment. Only swollen mitochondria were visible due to their lower density in the phase 
contrast (right). Scale 10 µM. 
 
Further experiments were performed to investigate the effects of DFX-induced 
mitochondrial swelling on other cellular organelles. Co-imaging of mitochondria with 
microtubules revealed that swollen mitochondria post DFX displayed less dynamic 
trafficking than mitochondria in control cells. Microtubuli were observed to be wrapped 
around swollen mitochondria (Figure 15). 
 
 
Figure 15: Effect of swollen mitochondria on the microtubular network. OK cells transfected with 
Bacmam Mito GFP were stained with SiRtubulin (+ Verapamil). Scale = 10 µm. 
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Similar observations could be made when OK cells were stained for the endoplasmatic 
reticulum (ER, Figure 16). In DFX treated cells the ER appeared to surround the single, 
swollen mitochondria. 
 
 
Figure 16: Effect of 200 µM DFX (30 min) on endoplasmic reticulum (ER). OK cells were stained with 
ER tracker and Mitotracker DR. ER seems to surround single, swollen mitochondria. Scale = 10 µm.  
 
During time series recordings of swollen mitochondria impacted by DFX, we observed that 
rounded mitochondria formed short-lived (seconds) protrusions (Figure 17). Those 
protrusions - so called nanotunnels170 - appear as a response to stress in the cell, caused 
most likely by the combination of DFX-induced swelling and laser excitation. Their transient 
existence probably explains why they are rarely observed in fixed specimens. When 
performing live imaging in control cells we did not observe nanotunnels. 
Results  
52 
 
Figure 17: Appearance of transient mitochondrial nanotunnels during fast (1 frame per second) 
imaging of OK cells stained with TMRM and treated with 200 µM DFX for 25 min. Scale = 2 µm. 
 
After describing the phenotype of DFX by live cell imaging, we wanted to confirm these 
results in fixed cells to gain an even higher resolution of mitochondrial morphology and to 
exclude that live imaging interferes with DFX induced toxicity (for example, due to laser 
toxicity). We utilized an antibody staining for the outer mitochondrial membrane, TOM-20, 
for the visualization of the mitochondria by STORM. Using this approach, we were able to 
confirm the swelling of mitochondria, without prior impact of laser damage (Figure 18).  
 
 
Figure 18: 3D STORM super resolution images of TOM-20 stained mitochondria treated with 200 µM 
DFX for 30 min and control (left). Mitochondrial swelling is only apparent in DFX-treated sample. 
Scale = 3 µm. (Imaging and image processing conducted by Dominik Hänni) 
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To gain insights into the state of the inner mitochondrial membrane, OK cells were fixed by 
high pressure freezing after treatment with control or DFX. After dehydration and 
embedding we were able to depict mitochondrial morphology using TEM. In the overview 
(Figure 19, upper panels) there was already an obvious difference between DFX and 
control, since DFX mitochondria were visible as light, big, round structures. With greater 
magnification (Figure 19, lower panels) the difference between the two treatments is even 
more impressive. In control cells mitochondria had normal cristae and the matrix appeared 
to be darker than the cytosol, indicative of a high protein density. In DFX treated cells the 
mitochondria were swollen, cristae were disrupted, and the matrix density was reduced. 
 
 
Figure 19: TEM images of high pressure frozen OK cells treated with 200 µM DFX for 60 min and 
control. Even in low magnification (upper row), swollen mitochondria are detectable as lighter white 
spots. (Scale 10 µm). With higher magnification it becomes obvious, that upon treatment with DFX 
the matrix density is decreased, and the inner membrane is pushed towards the outer one. Scale 1 
µm. 
 
As a result, we were able to determine - using different methods - that DFX induces toxicity 
by interfering with mitochondrial morphology, leading to swollen organelles. 
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3.1.2 Swollen mitochondria are vulnerable to rupture  
During recording of fast time series of swollen mitochondria stained with TMRM, the 
mitochondrial signal seemed to disappear and reappear during the measurement, a 
phenomenon only rarely occurring in healthy mitochondria.  
 
 
Figure 20: Characterization of mitochondrial flickering post DFX. (A) OK cells expressing CellLight 
Mitochondria-GFP BacMam 2.0 stained with TMRM for automated tracking of ΔΨm after a 30 min 
treatment with 200 µM DFX. Scale = 5 µm. (B) Example of single mitochondria fluorescence 
trajectories of laser induced blinking post DFX. Mito-GFP intensity (green area) is used for tracking 
and TMRM intensity (red area) is used as a readout for ΔΨm.(C) Cumulative 2D histogram of Mito-
GFP and TMRM signals shows two populations for TMRM but no correlation between Mito-GFP and 
TMRM indicating that the Mito-GFP signals remain even after the laser induced loss of ΔΨm. The 
dashed line indicates an intensity threshold of 15 which was used for discriminating between 
polarized and depolarized mitochondria. (D) Plot of the time evolution of the fraction of polarized 
mitochondria under a continuous illumination regime. 
 
 
A 
B 
C D 
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To investigate this instability, or ”flickering”, of the mitochondrial membrane potential, OK 
cells were transfected with a mitochondrial targeted GFP (CellLight Mitochondria GFP, 
BacMam 2.0). This ensured that mitochondria remain detectable with the GFP although the 
TMRM signal is lost (Figure 20 A) and enabled an automated analysis (performed by 
Dominik Hänni) of the fluctuations of the TMRM signal. The GFP signal (green trace) was 
stable during the measurements, whereas the intensity of the TMRM signal (red trace) 
switched rapidly between two states (Figure 20 B). Summarizing all traces confirmed that 
mitochondria were either polarized or depolarized (Figure 20 C). During the prolonged 
observation time it became apparent that mitochondria were more likely to be depolarized 
during later time points in the measurement (Figure 20 D), suggesting that swollen 
mitochondria were more vulnerable to laser induced rupture. 
 
Subsequent experiments performed without repetitive laser illumination confirmed that 
swollen mitochondria post DFX exist in two states – polarized and depolarized (Figure 21) 
- and eventually lose their potential. The time frame of sustained depolarization, however, 
was much longer without laser illumination, and the fraction of depolarized mitochondria 
only started to substantially decline without pre-illumination after 2 hours of DFX treatment 
(Figure 21). One likely explanation for the loss of potential in swollen mitochondria of DFX 
treated cells was found during the morphological screening using EM. Some mitochondria 
were not only swollen, but also showed a ruptured membrane (Figure 21), which most likely 
occurred due to increased pressure within the mitochondrion, perhaps explaining why it 
takes some time until loss of potential is detectable without pre-illumination of the 
mitochondria. The short-term loss of potential probably reflects a higher vulnerability to laser 
damage due to the swollen state of the mitochondria. Thus, we were able to show that DFX-
induced swelling increases the vulnerability of mitochondria to rupture. 
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Figure 21: Long term no laser pre-illumination experiments to derive mitochondrial depolarization 
kinetics in the absence of laser induced effects. The 2D Histogram again shows two populations for 
the TMRM signal but only one for the Mito-GFP signal. An intensity threshold of 6 (dashed line) was 
used to derive the time evolution of the fraction of polarized mitochondria. Compared to the 
continuous illumination experiments, the magnitude of depolarization was significantly lower, and the 
timescales dramatically extended. A moving average of 40 minutes (blue line) was included to better 
show the overall trend of spontaneous DFX induced mitochondrial depolarization. TEM of control 
and DFX (30 min 200 µM) treated cells. Arrows mark ruptures of the outer membrane. Scale = 1 µm. 
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3.2 Understanding the mechanism of DFX induced toxicity 
3.2.1 DFX toxicity is due to an off-target effect 
After describing the morphological changes DFX induces, the mechanism of DFX induced 
toxicity was further investigated.  
Since DFX was designed as a drug to bind iron for excretion, the first question to answer 
was whether DFX induced toxicity is due to the chelation of iron in the cell or due to an off-
target effect. As discussed earlier, iron is extremely important for a range of mitochondrial 
functions.  A simple way to investigate this was to compare DFX with other clinically used 
iron chelators, namely Deferoxamine (DFA) and Deferiprone (DFP). Neither of those iron 
chelators induced mitochondrial swelling in OK cells, despite the prolongation of the 
incubation time to 5 h and the addition of pluronic to increase cell permeability and drug 
uptake (Figure 22).  
Therefore, it is more likely that DFX toxicity is rather due to an off-target effect than its ability 
to chelate iron. 
 
 
Figure 22: DFX toxicity is due to an off-target effect. Only after treatment with DFX 200 µM 30 min 
mitochondrial swelling was detectable with TOM-20 staining in OK cells. Other iron chelators (DFA, 
DFP; 200 µM, 5 h) were not able to recreate the phenotype despite a much longer incubation period. 
Scale = 10 µm. 
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3.2.2 DFX does not inhibit respiration or induce oxidative stress 
In order to determine the target of DFX induced mitochondrial toxicity, the most commonly 
suspected pathways of drug induced mitochondrial damage – interference with respiration, 
induction of oxidative stress and opening of the mPTP - were investigated. 
First the effect of DFX on oxidative phosphorylation was investigated using oxygen 
consumption measurements. After addition of DFX to OK cells, respiration was slightly 
increased compared to control, but showed no difference when respiration was stimulated 
with TMPD/Ascorbate, or afterwards blocked by inhibiting complex IV with cyanide (Figure 
23, left). Additionally, it was investigated whether DFX could be oxidized by complex IV in 
a peroxidase mechanism, causing an increase of water inside the mitochondria and 
explaining the rapid swelling. However, DFX addition to Antimycin A treated cells (to block 
complex III) did not increase oxygen consumption, disproving the possibility of a functional 
interaction between DFX and complex IV (Figure 23, right). 
 
 
Figure 23: Oxygen consumption in OK cells is not altered in response to DFX. Left: After addition of 
DFX (200 µM), a slight increase in oxygen consumption rate compared to control was observable. 
After stimulation of respiration by the addition of 500 µM TMPD (2 mM Ascorbate) and blockage of 
complex IV with 2 mM Cyanide, there was no difference between control and DFX, showing that DFX 
does not inhibit respiration in OK cells. Right: After blocking complex III by adding 2.5 µM Antimycin 
A, DFX was not able to stimulate respiration and therefore it cannot directly donate electrons to 
complex IV.  
 
In addition, it was investigated what effect increasing respiratory chain activity has in DFX 
treated cells by live imaging. In control cells the addition of TMPD/Ascorbate (500 µM, 2 
mM), which increases electron supply to cytochrome c, did not alter the energization or 
morphology of mitochondria (Figure 24). On the other hand, when TMPD/Ascorbate was 
added to cells that had already been treated with DFX, a rapid, generalized depolarisation 
occurred. An explanation for this effect is that swollen mitochondria are more vulnerable to 
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stress that usually would not cause any damage in the cell, similar to the observed increase 
of laser induced damage in DFX mitochondria. 
 
 
Figure 24: Stimulation of respiration by addition of 500 µM TMPD together with 2 mM Ascorbate after 
DFX treatment induced a rapid, generalized depolarisation of mitochondria. With DFX alone only 
mitochondrial swelling was observed, whereas with only TMPD/Ascorbate no changes in morphology 
or polarisation were detected. Scale = 10 µm. 
 
These observations led to the question whether DFX induced mitochondrial swelling and 
rupture is mediated via an induction of oxidative stress, leading to lipid peroxidation and 
degradation of the mitochondrial membranes. At first, it was investigated whether the 
mitochondrial targeted antioxidant peptide SS-31 could prevent or improve DFX-induced 
damage. SS-31 was shown previously to reduce ischemic kidney injury and apoptosis165, 
171. OK cells were pre-incubated with 500 µM SS-31 for 1 h before DFX was added. The 
antioxidant was neither able to prevent mitochondrial swelling by DFX nor able to reduce 
the laser induced rupture of mitochondria (observed as flickering of potential) (Figure 25). 
 
 
Figure 25: Treatment with the antioxidant SS31 did neither prevent DFX induced swelling nor 
fluctuations in potential. Shown are color-coded projections of the time series that were recorded 
with 1 frame per second for 2 min of OK cells stained with TMRM and treated with DFX (200 µM, 34 
min), DFX and SS31 (90 min SS-31 500 µM and 31 min DFX) or SS31 only. Each colour represents 
the time point the mitochondrion had been polarized. If a mitochondrion was polarized during the 
whole observation time it appears white in this plot. Scale = 10 µm. 
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Another line of evidence that DFX does not act via the induction of oxidative stress was 
determined by the measurement of intracellular hydrogen peroxide levels and by the 
measurement of lipid peroxidation (which could be an explanation for the ruptures in the 
mitochondrial membrane). 
The transfection of OK cells with the hydrogen peroxide sensor Premo enabled the 
estimation of intracellular peroxide levels by a ratiometric measurement. After a 60 min 
treatment with DFX the ratio was no different to that of control cells, but the sensor per se 
did work as an incubation with the positive control (hydrogen peroxide) resulting in a 
doubling of the measured ratio (Figure 26 A).  
Similar observations were made with the lipid peroxidation detecting ratiometric dye Bodipy 
581/591 C11. Only in the peroxide treated sample did the ratio increase after a 1 h 
treatment, whereas no difference to control was visible with DFX (Figure 26 B). Taken 
together, these findings refute oxidative stress as the reason for DFX induced mitochondrial 
swelling and rupture. 
 
 
Figure 26: DFX does not induce oxidative stress. (A) Cellular levels of hydrogen peroxide measured 
using the ratiometric Premo Cellular Hydrogen Peroxide Sensor, Orp1-roGFP after 1 h treatment. 
For each condition 32 images were analyzed. 1-way ANOVA, posthoc Dunnett’s multiple comparison 
test, *** = p < 0.0001 (B) Lipid peroxidation after 1h treatment measured using Bodipy 581/591 C11. 
For each condition 16 images were analyzed. 1-way ANOVA, posthoc Dunnett’s multiple comparison 
test, *** = p < 0.0001. 
 
Cytochrome c has the ability to act as a peroxidase in response to cellular stress, which 
damages cardiolipin and hence the inner mitochondrial membrane172, 173. The antioxidant 
peptide SS-31 is thought to be protective upon ischemic injury due to an inhibition of 
peroxidase activity of cytochrome c166. DFX might interact with the iron core of cytochrome 
c, leading to an increase in peroxidase activity and peroxidation of cardiolipin.  
The activity of the peroxidase was measured using an Amplex Red assay. Upon addition of 
cardiolipin the peroxidase activity was increased, as described previously168. Treatment with 
DFX did unexpectedly inhibit the peroxidase activity in a concentration dependent manner 
(Figure 27). 
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Figure 27: Effects of DFX on cytochrome c (400 nM) peroxidase activity measured by Amplex Red 
assay. The addition of 30 µM cardiolipin (CL) enhanced peroxidase activity of cytochrome c, which 
was reduced upon addition of 200 µM DFX. Right: The inhibition of peroxidase activity by DFX was 
concentration dependent. 1-way ANOVA, posthoc Dunnett’s multiple comparison test, *** = p < 
0.0001; ** = p < 0.001; * = p < 0.05 
 
3.2.3 DFX induced swelling is independent of the mitochondrial 
permeability transition pore (mPTP) 
Another commonly proclaimed and hotly debated mechanism for mitochondrial toxicity is 
the opening of the mPTP (see 1.3.3). If DFX was to induce an opening of the pore, a 
fluctuation in mitochondrial calcium signal would be expected. Mitochondrial  membrane 
potential (Rhodamine 123) and calcium (XRhod) were imaged simultaneously in OK cells 
that had been treated with DFX. Whilst flickering of the mitochondrial membrane potential 
was observed as expected, no changes in mitochondrial calcium occurred, indicating that 
the flickering is not due to the opening of the mPTP (Figure 28). 
 
 
Figure 28: Flickering of mitochondrial membrane potential post DFX is not associated with changes 
in mitochondrial calcium. Shown are ttemporal color coded images of time series (1 frame per 11 s, 
308 s recording) of DFX treated cells stained with Rhodamine 123 (potential) and XRhod (calcium). 
Scale = 10 µm. Right: Plotted traces of different ROIs of XRhod intensity. No flickering was 
detectable. 
 
Additionally, to the tracking of the calcium signal, pre-treatment of OK cells with an inhibitor 
of the mPTP, Cyclosporine A, did not prevent mitochondrial swelling or flickering in 
response to DFX (Figure 29). 
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Figure 29 Temporal color coded images of time series (120 frames, 1 frame per s) of cells treated 
with control, DFX (24 min), or DFX and mPTP inhibitor Cyclosporine A (47 min CsA 1 µm and 32 
min DFX 200 µm). Blocking of mPTP did not influence DFX induced swelling and blinking. Scale = 
10 µm. 
 
Another method frequently used to observe opening of the mPTP is staining with Calcein-
AM174, 175. In case of a pore opening, the mitochondrial signal would decrease, since the 
dye can leave the mitochondrion through the pore. On the contrary, we observed a slight 
increase in mitochondrial calcein signal together with a decrease of the cytosolic signal, 
further indicating that the opening of the mPTP is not involved in DFX induced toxicity. 
 
 
Figure 30: Calcein signal in mitochondria was not decreased post DFX indicating that mPTP is not 
opening. Scale = 10 µm. 
 
Finally, it was investigated whether DFX induces a release of cytochrome c, a known 
mechanism of induction of mitochondrial induced apoptosis176. Since the available 
antibodies did not work in OK cells, most likely due to species differences, cytochrome c 
staining was performed in COS-7 cells (fibroblast kidney cell line). Also, in these cells 
mitochondria swelled rapidly (10 min) in response to 200 µM DFX, as seen with TOM-20 
staining (Figure 31). Cytochrome c was localized within the borders of the outer membrane 
marked by TOM-20 in both control and DFX treated cells. So DFX did not induce a release 
of cytochrome c from the mitochondria. 
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Figure 31: STED images of COS7 cells stained for cytochrome C and TOM-20 after control and 200 
µM DFX treatment for 10 min. DFX induced swelling of the mitochondria but no release of cytochrome 
C. Scale = 1 µm. Staining and imaging performed by Claus Schuh. 
 
Taken together, and using four different experimental strategies – calcium imaging, 
pharmacological inhibition, dye leakage and cytochrome C release – it was shown that DFX 
does not induce the opening of the mPTP. Therefore, DFX induced mitochondrial swelling 
must occur due to a different mechanism. 
 
3.2.4 DFX toxicity is independent of respiratory chain function 
Since the classical pathways of mitochondrial toxicity – respiration inhibition, induction of 
oxidative stress and opening of the mPTP - were not affected by DFX, the next step in 
understanding the mechanism of DFX toxicity was to further investigate how the rapid 
swelling might occur mechanistically. Previous studies in isolated mitochondria have 
suggested that mitochondrial swelling under certain circumstances can occur due to excess 
water production by the respiration chain177. Since the water production is an active process, 
swelling was inhibited by blockage of respiration in these studies.  
To investigate the role of the respiratory chain in DFX induced mitochondrial swelling, OK 
cells were pre-treated with different respiratory chain inhibitors, before DFX was added, and 
cells were fixed and stained for TOM-20. Inhibition at different points of respiratory chain 
(complex III by 2.5 µM antimycin A, complex IV by 2 mM cyanide or complex V/ATP 
synthase by 10 µg/ml Oligomycin) 10 min prior to DFX treatment did not prevent subsequent 
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mitochondrial swelling (Figure 32). Additionally, swelling was also independent of 
mitochondrial polarization, since pre-treatment with the protonophore FCCP (10 µM, 1min) 
was also not able to prevent the morphological changes in mitochondria. 
 
 
Figure 32: TOM-20 staining in OK cells pre-treated for 10 min with the complex III inhibitor antimycin 
A (2.5 µM), the complex IV inhibitor cyanide (2 mM), or the ATP synthase inhibitor oligomycin (10 
µg/ml), or for 1 minute with the uncoupler FCCP (10 µM) before addition of 200 µM DFX. No 
interventions with the respiratory chain were sufficient in inhibiting DFX-induced mitochondrial 
swelling. 
 
3.2.5 DFX induced swelling is not explained by an increased inner 
membrane permeability 
Another way of introducing mitochondrial swelling experimentally is to change the 
permeability of the inner mitochondrial membrane. The mitochondrial detergent 
dodecyltriphenylphosphonium (DTPP, used for targeting drugs to mitochondria by its 
amphiphilic structure, for example, the mitochondrial targeted antioxidant MitoQ178), which 
intercalates into the inner mitochondrial membrane179 and therefore changes the 
membrane’s properties, caused acute mitochondrial swelling in OK cells, as expected. 
However, in contrast to DFX, 500 nM DTPP also led to an abrupt depolarization of the 
mitochondrial membrane potential (Figure 33). 
The potassium ionophore Valinomycin renders the inner mitochondrial membrane 
permeable to K+, which enables diffusion of K+ across the concentration gradient into the 
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mitochondria, and also leads to mitochondrial swelling180. Similar to DTPP we could observe 
mitochondrial swelling and depolarization in OK cells with 10 nM Valinomycin, as expected 
(Figure 33). Thus, two experimental agents that are known to increase mitochondrial inner 
membrane permeability could recreate acute mitochondrial swelling similar to DFX, but in 
both cases, this was associated with rapid dissipation of potential, which was not observed 
in DFX treated cells. 
 
 
Figure 33: Live confocal imaging of OK cells stained with TMRM revealed that interference with the 
integrity of the inner mitochondrial membrane by the detergent DTPP 
(Dodecyltriphenylphosphoniumbromide) or the potassium ionophore Valinomycin induces 
mitochondrial swelling and depolarization. Scale = 10 µm. 
 
To further investigate whether DFX has an effect on the permeability of the inner 
mitochondrial membrane, an established artificial liposome model resembling the inner 
mitochondrial membrane was used164. Liposomes containing 20 % cardiolipin were loaded 
with the fluorescent dye calcein at a sufficiently high concentration (50 mM) to cause self-
quenching. When the liposomes rupture they release the dye, leading to a dequenching of 
calcein signal, and therefore an increase in fluorescence. Additionally, to DFX liposomes 
were treated with the detergent Triton-X and DTPP (which is known to change the properties 
of the inner mitochondrial membrane) as positive controls. As expected, both controls did 
induce the release of calcein, whereas DFX did not, even with a high concentration of 1 mM 
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(Figure 34). These results provide further evidence that DFX induced mitochondrial swelling 
is not explained by a direct effect on the permeability of the inner membrane. 
 
 
Figure 34: DFX did not increase calcein leakage from liposomes (500 ng/ml) resembling the inner 
mitochondrial membrane, even at a concentration of 1 mM. In contrast, DTPP and the detergent 
Triton-X (0.5%) both increased calcein release, indicating a change in membrane permeability. Right: 
Calcein fluorescence values after 4 minutes of drug addition, normalized to baseline measurements 
did not show significant increase after DFX. 1-way ANOVA, posthoc Dunnett’s multiple comparison 
test (*** = p < 0.0002, ** = p <0.01, n=3). 
 
3.2.6 DFX is not taken up via endocytosis 
Since DFX is circulating in the blood mainly bound to plasma proteins like albumin130 and 
proteins enter the PT cell via endocytosis32, it was investigated whether DFX enters the PT 
cells via endocytosis. 
The cytoskeleton as a highway for cellular uptake was disturbed by the blocking of tubulin 
polymerization using Colchicine181 (20 µM, 1 h prior to DFX), or by inhibiting actin formation 
using Cytochalasin D182 (20 µM, 40 min prior to DFX). Receptor mediated endocytosis was 
reduced by the inhibition of HMG-CoA with Simvastatin183 (10 µM, 24 h prior to DFX) and 
megalin/cubilin mediated endocytosis was blocked by RAP184 (1 µM, 30 min prior to DFX). 
None of these attempts to block endocytosis were successful in stopping DFX-induced 
mitochondrial swelling (Figure 35), suggesting that this pathway is not important for uptake, 
at least for the free drug. 
Results 
67 
 
Figure 35: Inhibition of endocytosis did not prevent DFX-induced mitochondrial swelling. OK cells 
(stained with TMRM) were treated with different blockers before DFX was added. Tubulin 
polymerization was inhibited by Colchicine (20 µM, 1 h) and actin polymerization by Cytochalasin D 
(20 µM, 40 min). Receptor mediated endocytosis was reduced by a 24 h incubation with 10 µM 
Simvastatin prior to the experiment. RAP (1 µM, 30 min) was used to inhibit megalin/cubilin mediated 
endocytosis. Scale = 10 µm. 
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3.2.7 DFX induced swelling is preventable and rapidly reversible 
The experiments so far suggested that DFX is highly toxic to mitochondria, which raises the 
question of how it can, in general, be relatively well tolerated in patients. In vivo DFX is 
highly (99%) bound to albumin in the bloodstream. When similar conditions were created in 
vitro by a short (5 min) pre-incubation with 200 µM albumin, no mitochondrial swelling in 
response to DFX was observed, suggesting that only the free drug causes toxicity (Figure 
36 A). Indeed, the treatment with DFX and albumin markedly improved cell viability after 24 
h, compared to the free drug alone (Figure 36 B). 
 
Figure 36: Albumin binding prevents DFX induced toxicity. (A) OK cell stained with TMRM and treated 
for 5 min with 200 µM albumin, before the addition of 200 µM DFX. No acute swelling of mitochondria 
was subsequently observed. Scale = 10 µm. (B) Albumin preserves cell viability after DFX (200 µM) 
treatment for 24 h. 1-way ANOVA, posthoc Dunnett’s multiple comparison test (*** = p < 0.0001, 
n=3). 
 
To confirm that only unbound DFX is toxic to PT cells, DFX was pre-bound to its target iron 
before it was added to OK cells. In the bound form DFX was not able to induce swelling of 
mitochondria (Figure 37). 
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Figure 37: Addition of 200 µM DFX bound to 200 µM iron (III) to TMRM stained OK cells did not 
induce mitochondrial swelling. Scale = 10 µm. 
 
Iron not only prevented DFX toxicity, but also reversed it. When iron (III) was added to OK 
cells, that had been treated with 200 µM DFX for 10 min, mitochondria reformed their 
original elongated shape 10 min after the addition of iron and depolarized mitochondria were 
observed to re-energize (Figure 38). These observations further confute the existence of 
mPTP opening, since such a catastrophic event would most likely not be so rapidly 
reversible. 
 
 
Figure 38: 10 min after DFX (200 µM) treatment, the addition of 200 µM iron (III) reverses 
mitochondrial swelling within 10 min. 
 
3.2.8 Diclofenac induces a similar phenotype to DFX 
DFX is manufactured from the NSAIDs salicylic acid and 4-hydrazinobenzoic acid. In older 
studies the NSAIDs Diclofenac and salicylic acid were both associated with mitochondrial 
swelling in kidney and liver, respectively185, 186. The building blocks of DFX, salicylic acid (10 
mM) and 4-hydrazinobenzoic acid (500 µM), did not cause acute mitochondrial swelling in 
OK cells in vitro, even when used in higher concentrations than DFX (Figure 39). This is an 
indication that the complete drug is needed to cause mitochondrial toxicity. 
Diclofenac, on the other hand, did cause acute mitochondrial swelling in OK cells while 
mitochondrial membrane potential was maintained (Figure 39), similar to the effect of DFX. 
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Both DFX and diclofenac are highly lipophilic, organic weak acids, which might be the 
common feature in the shared effect of mitochondrial toxicity. Moreover, the fact that a non-
iron chelator can recreate the effect of DFX on mitochondria provides further evidence that 
it is an off target phenomenon. 
 
 
Figure 39: No mitochondrial swelling occurred in response to the starting materials of DFX synthesis, 
salicylic acid (10 mM, 140 min) or 4-hydrazinobenzoic acid (500 µM, 70 min). The NSAID diclofenac 
(500 µM, 64 min) on the other hand did induce mitochondrial swelling, whilst the mitochondria 
remained energized.  
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3.3 Effect of DFX on kidney cortex 
Due to the limitations of an in vitro system, and due to our finding that albumin binding 
seems to play an important role in DFX mediated nephrotoxicity, the effects of the iron 
chelator were further evaluated in native kidney tissue and in an in vivo mouse study. 
3.3.1 DFX induces mitochondrial swelling in cortical kidney slices 
First, to investigate whether DFX causes acute mitochondrial toxicity in native kidney 
tubules, live imaging experiments were performed in freshly prepared slices of mouse 
kidney cortex tissue, where the drug could be applied under tightly controlled experimental 
conditions. 
Observations of the cell model could be confirmed as acute mitochondrial swelling was 
detectable in response to 200 µM DFX (Figure 40). The swollen mitochondria remained 
polarized although the NAD(P)H signal decreased. Subsequent flickering of mitochondrial 
potential could also be observed in the slice model. The mitochondrial swelling occurred not 
only in the PT, but also in the distal tubule and the thick ascending loop of Henle. 
 
Figure 40: Live multiphoton imaging of cortical kidney slices stained with TMRM showed that 200 µM 
DFX induced a loss of NAD(P)H signal and rapid mitochondrial swelling without loss of mitochondrial 
membrane potential (ΔΨm). Scale = 10 µm. 
 
After confirming that DFX induced mitochondrial swelling in kidney slices, the reversibility 
of toxicity was investigated. The addition of iron did, comparable to the results in OK cells, 
reverse the swelling within 10 min, after the slice had been treated with 200 µM DFX for 20 
min (Figure 41 A). An explanation for the reversibility could be that iron either replenished 
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cellular iron level, or, alternatively bound free DFX. To distinguish between those two 
options, DFX exposed kidney slices were treated with copper, which also has an affinity to 
the chelator DFX. Like iron, copper also reversed the swelling of mitochondria post DFX 
(Figure 41 B). This further supports our in vitro findings that DFX toxicity is due to an off-
target effect.   
 
Figure 41: Addition of 200 µM iron (A) or 200 µM copper (B) post DFX reversed mitochondrial swelling 
in cortical kidney slices. Scale = 10 µm. 
 
Removal of DFX after 30 min incubation had a similar effect as binding of the chelator by 
ions, since mitochondria regained normal structure as soon as 8 min after drug removal 
(Figure 42). This suggests that DFX is probably not tightly bound within the cell. 
 
 
Figure 42: Washing off 200 µM DFX after 30 min also reversed the morphological changes of 
mitochondria in kidney slices. Scale = 10 µm. 
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3.3.2 DFX induces mitochondrial swelling in the proximal tubule in vivo 
To investigate the effects of DFX in vivo, intravital multiphoton and electron microscopy 
were used. To model toxicity in humans, mice were given an intraperitoneal daily dose of 
100 mg/kg bodyweight DFX for 10 days (similar dosing has been described to induce renal 
Fanconi syndrome in rats187). 
Intravital multiphoton microscopy revealed that the damage of DFX is localized to the PT in 
the kidney. In the blue autofluorescence signal debris was detectable only in the lumen of 
PTs of DFX treated animals, and not in control treated mice, showing that DFX induced 
localized cell damage (Figure 43 A).  
The mitochondrial TMRM signal was more heterogeneous in DFX mice, compared to 
control, indicating variations of the mitochondrial membrane potential. Furthermore, 
individual elongated mitochondria were no longer distinguishable, consistent with 
mitochondrial swelling (Figure 43 B).  
To measure whether protein uptake was affected by DFX (the main criterion for Fanconi 
syndrome), fluorescently labelled albumin was injected intravenously during live imaging. 
In control animals, albumin was taken up homogenously across the brush border. In DFX 
treated animals, albumin was filtered normally, but the uptake of protein into the PT was 
irregular and protrusions of the apical PT membrane into the lumen were visible (Figure 43 
C).  
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Figure 43: Intravital multiphoton microscopy of DFX treated (100 mg/kg bodyweight i.p., 10 days) 
mice. (A) Autofluorescence showed luminal cell debris from cell shedding only in DFX treated mice. 
Scale = 30 µm. (B) Mitochondrial energization, evaluated by TMRM staining, was heterogeneous in 
DFX animals. Moreover, the normal elongated morphology of mitochondria was no longer observed 
in DFX animals. Scale = 30 µm. (C) Fluorescently labelled albumin was injected intravenously to 
visualize protein uptake in the PT. Albumin was filtered in both control and DFX mice, but taken up 
heterogeneously in DFX animals, resulting in protrusions of the PT membrane into the tubular lumen. 
Scale = 30 µm. (Experiment performed by Claus Schuh) 
 
To validate the findings that mitochondrial swelling occurs in vivo only in the PT, electron 
microscopy was performed on kidneys of control and DFX treated animals. Swollen 
mitochondria, with lower matrix density and cristae pressed towards the outer membrane, 
were detectable solely in the PT of DFX treated animals. Other tubular segments of DFX 
treated animals were not affected, and there were no signs of damage in any tubular 
segments in control mice (Figure 44). 
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Figure 44: Electron microscopy images of kidneys from control and DFX treated mice. No signs of 
changes in mitochondrial morphology were observed in control and in the DT of DFX treated animals. 
In PTs of DFX treated mice swollen mitochondria with decreased matrix density and displaced inner 
membranes were detected. Scale = 1 µm. Images taken by Susan Ghazi. 
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4 DISCUSSION 
4.1 Limitations of predicting nephrotoxicity of drugs 
4.1.1 The problem of drug-induced nephrotoxicity is increasing 
Drug toxicity limits the effectiveness of otherwise successful therapies, which is a 
fundamental problem in fighting diseases. Highly metabolic active organs that also have a 
great exposure to the blood stream including the circulating drugs/toxins are at high risk of 
developing toxicity. Liver and kidney are the most commonly affected organs in drug 
induced injury188. Both organs receive, with 20 % to 25 % each, a high amount of the cardiac 
output, although they only contribute to a low percentage of the whole body weight, resulting 
- compared to other parts of the body - in a relatively higher concentration of circulating 
drugs per cell189. Especially in the kidney where PT cells not only have to reabsorb solutes 
after primary filtration, but also have to ensure excretion of molecules, a fine balance can 
be easily disturbed leading to failure of the renal system and other systems such as acid 
base homeostasis1. Globally, the incidence of AKI has steadily increased, which, in part, is 
due to the increased number of prescriptions of nephrotoxic drugs190. Twenty percent of 
hospital-acquired AKI is induced by drugs or toxicants11. Since AKI is associated with an 
increased morbidity and mortality2, 3, it would be beneficial to avoid these problems by  
developing drugs with decreased nephrotoxic potential. However, the prediction of 
nephrotoxicity during preclinical drug development is difficult, and the nephrotoxic potential 
of drugs in development is often underestimated191, 192.  
Nephrotoxicity is only detected late in drug development and accounts for 2 % of drug 
withdrawal in preclinical studies and 19 % during phase III192. One reason for the late 
detection of adverse effects is the lack of efficient and accurate biomarkers that translate 
well from preclinical testing to clinical studies188. In clinical trials, nephrotoxicity is evaluated 
by the measurement of blood urea nitrogen and creatinine, both markers that only deviate 
from normal values when 50 % of the GFR has been lost193, 194. Novel biomarkers that have 
been reported to work in patients, like KIM-1 and NGAL193, 195, are already upregulated in 
cultures of rat PT cells, limiting their use for in vitro assays196, 197. Other end points that are 
used as a readout in toxicity testing are cell viability, lactate dehydrogenase (LDH) leakage, 
GSH depletion or ATP depletion. All of these markers show low sensitivity and high false 
rates198. There is a pressing need to improve the methods for detecting kidney injury already 
in the state of in vitro assessment of potential nephrotoxic drugs. The use of advances in 
technology, like metabolomics or high content imaging, could aid in achieving this goal188. 
The use of metabolomics as method for predicting nephrotoxicity is limited due to the 
elaborate data analysis needed. Imaging, on the other hand, is a relatively straightforward 
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method to track changes in cellular morphology and physiology, way before markers like 
cell viability drop144.  
 
4.1.2 Imaging as a tool for detecting toxicity 
Live cell imaging therefore facilitates a general analysis of the intracellular changes enabling 
the identification of the target organelle of toxicity. Furthermore, mitochondrial dyes, for 
example, not only provide detailed structural information, but also allow tracking of the 
health of the organelle. The dye mainly used in this study, TMRM, effectively depicts the 
energization state of mitochondria via different intensities199, which is a key marker for 
mitochondrial activity. Other functional fluorophores can aid to determine levels of oxidative 
stress with the measurement of lipid peroxidation (Bodipy 488/581152) or the levels of 
intracellular hydrogen peroxide (Premo a transfectable sensor200). Arguments that imaging 
itself causes damage due to laser induced photo-toxicity have to be considered201. The laser 
power used on the sample needed to be adjusted to ensure that no visible alterations - like 
cell shrinking or bleaching of the dye - occur in a control setting (important when a new dye 
is established for usage). Additional analysis using immunofluorescent staining of fixed 
cells, electron microscopy or biochemical assays, can be used to underline and confirm the 
results obtained from the live cell imaging. Nevertheless, despite these caveats, live cell 
imaging has the big advantage of showing results in an (almost) self-explanatory, 
convincing way that is quickly understood. 
Although imaging is a powerful tool for investigating cellular changes and metabolism, some 
limitations can occur due to the model used. In vitro studies on proximal tubular cells are 
usually relatively straightforward, but performing intravital imaging can result in  significant 
technical challenges202. Usage of multiphoton microscopy enables the investigation of the 
outer cortical region of the kidney in the living mouse, but the imaging depth is limited to 
around 100 µm160. Although mitochondria can’t be resolved as clearly as with confocal life 
imaging of cells, an advantage of the in vivo studies is the possibility for uptake studies to 
be performed in the living animal by injection of fluorescently labelled molecules of interest, 
thus providing dual readouts of both transport and metabolism160. The gap between in vitro 
and intravital imaging can be closed by the use of multiphoton microscopy of fresh, cortical 
kidney slices203. Compared to the in vitro situation, cells in kidney slices are arranged in 
their tubular environment and variations between different segments of the nephron can be 
investigated. The slices remain metabolically active similar to the situation in the animal – 
unlike tubular cells in tissue culture that depend more on glycolysis than on oxidative 
phosphorylation204, 205. The disadvantage of the kidney slices is that drugs/solutions can 
only be applied via diffusion and not via the vasculature. Additionally, tubular cells in the 
slice are exposed to much higher oxygen concentrations than in vivo, limiting the strength 
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of the model206. For a better and more complete understanding of cellular mechanisms of 
drug induced nephrotoxicity it is therefore necessary not only to perform traditional cell 
death assays, but to combine different models (in vitro, kidney slice, in vivo) with imaging 
techniques such as confocal live imaging, multiphoton microscopy, immunofluorescence, 
and electron microscopy. 
 
This study mainly used imaging techniques to investigate the mechanisms of drug toxicity 
induced by the iron chelator DFX. DFX is an important cause of drug induced renal Fanconi 
syndrome, but the mechanisms of the iron chelator causing this severe side effect were 
previously unknown119, 187. Since iron is a crucial cofactor in electron transport processes in 
the respiratory chain of the mitochondria61, and mitochondria are thought to be one of the 
primary targets of nephrotoxins95, it was hypothesized that DFX might cause Fanconi 
syndrome by chelating iron within the mitochondria and therefore altering mitochondrial 
function. 
 
4.2 DFX causes mitochondrial damage by the induction of 
swelling 
We were able to show in a cell model of the PT (OK cells), that DFX causes rapid (within 
minutes) mitochondrial swelling, without majorly affecting cell viability, which only 
decreased to 60 % after one day. Upon DFX treatment mitochondria formed transient 
protrusions (nanotunnels), before their motility was further decreased. Swollen 
mitochondria showed a destabilized mitochondrial membrane potential and gradually 
depolarized over a long period of time.  
 
Therapeutic plasma concentrations of DFX in patients receiving a daily dosing of 20-30 
mg/kg range from 100-200 µM130. When the rather poor end point of cell viability is used for 
the evaluation of toxicity198, DFX (200 µM)  only causes some degree of toxicity after one 
day. The more sensitive readout, live imaging of mitochondrial morphology, revealed that 
mitochondrial swelling actually occurs within minutes. There are several known causes for 
mitochondrial swelling: lipid peroxidation207, opening of the mPTP208, 209, excess water 
production177, 210, opening of a channel180, or changes in the mitochondrial membrane 
properties179, which were all examined in this study. Photoirradiation can induce 
mitochondrial swelling by increasing levels of ROS, which causes the mPTP to open211. 
This can easily be controlled by minimizing the light exposure of the cells. Imaging under 
the same conditions without DFX treatment did not induce mitochondrial swelling. 
Furthermore, mitochondrial swelling was also detectable without prior illumination using 
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chemically fixed samples for immunofluorescent staining and for electron microscopy. The 
mitochondrial swelling was therefore a direct effect of DFX, which was previously unknown. 
The process of mitophagy, the selective degradation of mitochondria by autophagy, starts 
with the endoplasmic reticulum surrounding the mitochondria to enable the transport 
towards the lysosomes212. During live imaging a change of the endoplasmic reticulum was 
observed after mitochondria swelled due to DFX. Although this might be indicative of the 
first step of mitophagy induction, further experiments, such as LC-II staining, are required 
to confirm that this process is triggered by DFX. 
The formation of nanotunnels upon DFX treatment matches the observation of reduced 
motility in the swollen mitochondria, as nanotunnels arise as a compensatory mechanism 
to promote mitochondrial communication in stress conditions170. They enable the transport 
of matrix and membrane proteins, and probably also smaller molecules, but are rather 
difficult to detect, since they are short-lived213. Upon DFX induced mitochondrial swelling, 
stress levels inside the organelle increase, which explains the higher vulnerability to rupture, 
that was visible by the destabilization of the mitochondrial membrane potential. The 
observed flickering in the fast-acquired movies, could potentially be explained by small 
ruptures in the mitochondria (depolarization), which might then be closed by reassembly of 
the membrane, thus explaining the repolarization. If DFX remains on the mitochondria, the 
swelling persists and eventually mitochondria will irreversibly rupture, as observed by 
electron microscopy.  
To the best of our knowledge, a phenomenon like this hasn’t been described before. It might 
be unique to DFX, or it might just not have been studied in such a detailed manner or be 
attributed erroneously to opening of the mPTP. 
 
4.3 DFX is toxic due to an off-target effect 
DFX toxicity could be explained by depletion of iron inside the mitochondria in PT cells119. 
However, other iron chelators are not known to cause Fanconi syndrome and even appear 
to be protective in acute kidney injury and ferroptosis76, 214. To clarify whether the toxicity of 
DFX is indeed due to its effect of chelating iron, or rather due to an off-target effect, the 
other clinically used iron chelators, DFA and DFP127, were also tested in our experimental 
setting to assess their ability to cause mitochondrial swelling. Since both chelators did not 
induce any changes in mitochondrial morphology or function, we concluded that DFX 
toxicity is most likely not due to the effect of chelating iron. Although addition of DFX bound 
to iron did prevent the development of mitochondrial swelling – confirming a recent study215 
- further experiments with other ions like copper showed that  this treatment can also prevent  
toxicity, implying that only the free, unbound DFX induces mitochondrial swelling. This 
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implies that although having the same target, namely iron, the three clinically used iron 
chelators are different in their toxicokinetics due to the difference in molecule properties. 
 
4.4 Toxicity of DFX was probably underestimated due to a 
lack of induction of classical toxicological markers 
4.4.1 DFX does not affect respiration 
DFX did not acutely inhibit oxygen consumption in mitochondria of OK cells. The iron 
chelator induced a small acute increase of the oxygen consumption rate but did not alter 
the capacity for maximal respiration (stimulation of cytochrome c via TMPD/ascorbate). 
When respiration was stimulated by addition of TMPD/ascorbate, which donates electrons 
to cytochrome c, an immediate and generalized depolarization was observable in swollen 
mitochondria post DFX treatment. Furthermore, DFX was not able to restore oxygen 
consumption when complex III was inhibited. 
Some mitochondrial toxins, such as fibrates and thiazolidinediones, undermine 
mitochondrial function by directly inhibiting the electron transport chain216, 217 or by 
uncoupling the electron transport from ATP synthesis218, 219. In both cases, the mitochondrial 
membrane potential can be dissipated150. DFX neither inhibits respiration nor dissipates the 
mitochondrial membrane potential. We could also exclude that DFX acts as an electron 
donor to cytochrome c in a Fenton type reaction (which would elevate oxidative stress), 
since addition of DFX after blockage of complex III did neither restore nor increase 
respiration220. 
PT cells in culture are supposedly more dependent on glycolysis than on oxidative 
phosphorylation205, wherefore measurements of oxygen consumption in these cells might 
be redundant. Nevertheless,  OK cells exhibit enough oxidative phosphorylation, maybe 
due to their endocytic activity162, to be detected by our sensitive method.  
Although DFX is clearly a mitochondrial toxin, the iron chelator did not alter oxidative 
phosphorylation and therefore induces mitochondrial toxicity via a novel pathway.  
 
4.4.2 Oxidative stress is not induced in response to DFX 
DFX did not increase intracellular levels of hydrogen peroxide, nor did it induce lipid 
peroxidation. Therefore, treatment with the mitochondrial targeted antioxidant SS-31, which 
stabilizes the connection of cytochrome c and cardiolipin and is known to prevent 
mitochondrial depolarization during insults such as ischemia166, 171, did not prevent DFX 
induced mitochondrial swelling or flickering. Moreover, in an in vitro assay, DFX inhibited 
the peroxidase activity of cytochrome c rather than enhancing it. 
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One way of mitochondrial toxins to harm the mitochondria is via induction of oxidative stress. 
Acetaminophen, doxorubicin and ethanol are examples for imposing oxidative stress via 
redox cycling or via glutathione depletion, cyp2E1-derived ROS generation or reactive 
metabolite formation221-223. Generated radicals can interfere with electron transport 
complexes and also induce lipid peroxidation224. Although fluctuations in mitochondrial 
membrane potential has been associated with bursts of oxidative stress225, we could not 
find any evidence of induction of ROS after DFX induced mitochondrial damage.  
Unexpectedly, we did find evidence of an inhibitory effect of DFX on cytochrome c 
peroxidase activity. Cytochrome c can act as a peroxidase in response to oxidative stress172, 
173. The peroxidase activity of cytochrome c damages cardiolipin, which is essential in the 
organization of the mitochondrial membranes226. In its native state cytochrome c is tightly 
folded, and its peroxidase activity is low, since all coordination positions in its heme iron are 
occupied166. The peroxidase activity increases upon partial unfolding or when the Met80-
Iron bond is weakened by interaction with cardiolipin, which we could confirm in our 
experimental setup227, 228. The mitochondrial targeted antioxidant SS-31 prevents cardiolipin 
from breaking the Met80-Fe coordination in cytochrome c, leading to a decreased 
peroxidase activity of cytochrome c, which explains the protective effect of SS-31in 
ischemia induced mitochondrial swelling166. Since cytochrome c has an iron core, we 
hypothesized that DFX might increase peroxidase activity of cytochrome c, but our data 
showed the opposite. 
However, the results of the Amplex Red assay have to be interpreted carefully, since it is 
measured only with the pure protein and not in a cellular context, where cytochrome c is 
imbedded in the mitochondrial membrane and is linked to other proteins, which might 
explain the discrepancy between the oxygen consumption and in vitro assay results. 
Moreover, if DFX itself acts as a substrate for peroxidases, this could also confound the 
interpretation of the Amplex Red assay. 
 
4.4.3 Opening of the mPTP cannot be used as an explanation for DFX 
induced mitochondrial swelling 
Numerous studies have explained mitochondrial swelling in pathological states by the 
opening of the mPTP208, 209, 229, including AKI due to ischemia-reperfusion injury165, 230, 231. 
However, the composition and the existence of the mPTP remains a topic of numerous 
discussions79, 232, 233. Many studies use cyclosporine A as an inhibitor of the opening of the 
mPTP, to prove involvement of the pore. However, mitochondrial swelling in response to 
DFX still occurred, when cyclosporine A was present. The usage of cyclosporine A as  proof 
for mPTP opening has to be taken with caution, since the drug has  pleiotropic effects and 
failed so far to be successful in clinical studies234.  
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Studies on mitochondrial swelling are typically performed reading the absorbance of 
isolated mitochondria at 540 nm, a method that has several drawbacks235. First, changes in 
light absorbance may not always reflect changes in matrix volume. Second, mitochondria 
are damaged during the isolation process and it is therefore not guaranteed that the 
complex architecture of the organelle remains stable. Usually no control measurements are 
made to prove that the mitochondria are still energized. Finally, no information can be 
obtained about mitochondrial behaviour in their native environment236.  
Other assays of mPTP opening in intact cells include the measurement of matrix calcium, 
release of the dye calcein out of the mitochondria, and release of cytochrome c (also used 
as an indicator of induction of apoptosis). After DFX treatment, no mPTP opening specific 
phenomenon was observable, showing that DFX induced mitochondrial swelling is most 
likely mediated via a new, unknown pathway. 
Before Haworth and Hunter described the mPTP in 1979237, which was henceforth often 
used as reason for mitochondrial swelling, the abnormal production of water during 
oxidative phosphorylation was used as an explanation, since inhibitors of the respiratory 
chain could prevent the swelling177, 210. Since mitochondrial swelling post DFX occurs in the 
absence of depolarization, a plausible rationale could be the excess production of water 
that does not interfere with voltage gradients. However, inhibition of respiratory chain 
activity did not influence DFX induced mitochondrial swelling. Nevertheless, it remains 
possible that an acute increase in water content within the mitochondrial matrix could 
explain why mitochondria remain polarized when swollen and why they appear less dense 
in the electron microscopic study. 
Opening of the mPTP is often used as a reason for mitochondrial swelling208, without full 
experimental proof. It should be considered that more than one experiment has to be 
conducted to convincingly explain mitochondrial toxicity by opening of the mPTP.  
 
4.4.4 DFX might affect mitochondrial membrane properties 
A change in the properties of the inner mitochondrial membrane induced by DFX could 
facilitate the entry of water and electrolytes into the mitochondrial matrix, thus explaining 
acute swelling. However, when the permeability for potassium was changed by treatment 
with Valinomycin180, a potassium ionophore, mitochondria did not remain polarized (unlike 
DFX). Similar observations were also made when OK cells were treated with DTPP, which 
integrates into the inner mitochondrial membrane and changes its properties179. Also, in an 
artificial liposome model resembling the features of the inner mitochondrial membrane, a 
direct effect of DFX on the membrane permeability was not observed. Nevertheless, an 
interaction with the bio-physical properties of the membrane could still be an explanation 
for DFX toxicity, since the chosen assay enabled us to only detect ruptures of the lipid 
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membrane, and not changes in fluidity, which would have to be measured using a lipid 
bilayer with single labelled lipids, allowing an analysis of fluidity. The change in fluidity might 
then allow the entry of water, without causing a depolarization of the voltage gradient. 
 
4.4.5 NSAIDs might induce kidney toxicity via a similar pathway 
The NSAID diclofenac, like DFX, induced mitochondrial swelling whilst the mitochondrial 
membrane potential was maintained, disproving the opening of the mPTP.  
While mitochondrial swelling upon NSAIDs was described, it was previously explained by 
the opening of the mPTP115, 116, 238. However, as discussed above, studies often attribute 
mitochondrial swelling to mPTP opening with insufficient hard evidence. It might be that 
both drugs share a previously unknown mechanism of toxicity, which could be explained by 
biochemical similarities. Both drugs, for example, are lipophilic and weak acids which might 
preferentially lead to a mitochondrial accumulation. However, this will need to be further 
investigated in future studies.  
 
4.5 DFX toxicity is localized in the PT due to its uptake 
mechanism 
The hypothesis of DFX directly interfering with the mitochondrial membrane could also be 
the explanation of why DFX induced swelling is preventable and rapidly reversible. Only the 
unbound drug appears to integrate (or interact) with the inner membrane, since the addition 
of iron prevents or reverses the phenomenon. The interaction of DFX with the membrane 
is therefore presumably weaker than an actual binding of the chelator to its target iron. 
Binding of DFX to albumin or copper and even just washing off the drug rapidly leads to 
reversibility of mitochondrial swelling, additional proof of a weak interaction of DFX with the 
inner membrane. 
One major question remaining from this study is how a drug, which induces such drastic 
adverse changes in mitochondrial morphology in vitro, does not cause generalized, instant 
damage to patients? Moreover, why is toxicity localized specifically to the PT? DFX induced 
swelling in other non-PT cell lines (COS-7 and mDCT). In addition, mitochondrial changes 
in the kidney slice were also observed in the distal tubule and the thick ascending loop of 
Henle. However, the specific localization of the damage to the PT was only detected in vivo. 
Since only the free drug causes toxicity in the cell model, the PT is presumably the specific 
site where DFX appears unbound. In the bloodstream, DFX is 99 % bound to albumin, 
preventing its acute toxic effect. Albumin is partially filtered by glomeruli239, 240 and is taken 
up by the early PT via receptor mediated endocytosis160, 241. Either DFX enters the cell 
bound to albumin, where it is then dissociated (for example by acidification in the eno-
lysosomal system43) or DFX is separated during filtration and occurs in low amounts as 
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unbound drug in the primary urine, where it can freely enter the cell (as blocking endocytosis 
in the OK cell model did not prevent toxicity of the free drug). The accumulation of DFX in 
the PT and little urinary excretion of the drug was already discovered in pharmacokinetic 
studies119, 242. Studies in intestinal Caco-2 cell monolayers suggested that DFX is most likely 
a substrate for the multidrug-resistance-associated protein (MRP2) or  with a higher affinity 
for the breast cancer-resistant protein BCRP, which could be confirmed in purified 
membrane vesicles130. In contrast, no transport by MDR1 (P-glycoprotein) was observed. 
Furthermore, experiments in Xenopus laevis oocytes did not show an involvement of 
organic anion-transporting polypeptide 1 OATP1A2, liver-specific organic anion 
transporters OATP1B1 and OATP1B3 or the human organic cation transporter OCT1130. 
Whatever the uptake mechanism is, it is likely that over time the amount of free DFX 
increases in PT cells, leading to the specific dysfunction of these cells and therefore to a 
Fanconi syndrome.  
 
4.6 Outstanding questions 
 
The exact mechanism of how DFX induces mitochondrial toxicity could not be revealed, 
although a number of potential explanations for DFX induced mitochondrial swelling could 
be disproven. The question arises whether there is an unknown biomarker that is more 
sensitive to mitochondrial injury than currently used readouts, such as oxygen consumption 
and cytochrome c release.   
It remains unclear whether DFX enters the PT cell bound to albumin or whether the chelator 
appears unbound in the urine enabling the drug to enter the PT cell freely. Further 
investigations on the effect of DFX on the inner mitochondrial membrane would also be 
helpful to determine whether DFX interacts with the MICOS complex243, with lipids like 
cardiolipin or other proteins. 
Not every patient taking DFX develops Fanconi syndrome, although there are several risk 
factors including age >65 years, pre-existing renal or comorbid conditions such as type 2 
diabetes mellitus, medicinal drugs that depress renal functions (NSAIDs or cyclosporine),  
or rapid iron removal244, 245. Most strikingly are patients with a higher reduction of iron burden 
more likely to develop nephrotoxicity246. These patients might have higher levels of the free 
drug, which would correspond to the data obtained in our experiments. 
Understanding mechanisms of drug induced toxicity is very important for several reasons. 
First of all, the discovery of the pathway of toxicity can give insight into pathological 
processes that are common in different organs. It can also help in understanding why 
putative treatments (for example mitochondrial targeted anti-oxidants247) are effective 
against some kidney insults but not others. Second, the study of toxicity can provide new 
Discussion 
85 
insights into basic physiological processes in cells, for example, how mitochondria swell in 
pathological states. Thirdly, and most importantly, gaining insight into the mechanisms of 
drug toxicity allows future drug design to avoid severe adverse effects. 
 
In summary, we discovered that DFX-induced kidney injury is explained by a previously 
unknown off-target effect, leading to mitochondrial dysfunction without causing respiratory 
chain dysfunction, oxidative stress or opening of the mPTP. Due to the novelty of the 
mechanism of toxicity, and due to the lack of biomarkers predicting nephrotoxicity, DFX was 
released to the market despite these dramatic side effects, causing it to be ranked second 
on the list of drug associated patient deaths by the ISMP in 2009117. These findings highlight 
that drugs can have unexpected side effects and that imaging can be a very handy tool in 
revealing novel mechanisms of drug toxicity. 
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5 SUMMARY 
Drug toxicity is a major cause of acquired kidney disease, but in most cases the 
mechanisms are unknown. The oral iron chelator Deferasirox (DFX) frequently causes renal 
Fanconi syndrome, a functional defect in the proximal tubule (PT), for previously unknown 
reasons. PT cells are densely packed with mitochondria, which require iron for normal 
metabolism. It has been postulated that DFX toxicity might occur due to the chelation of iron 
in mitochondria, but other clinically used iron chelators do not cause kidney injury. 
Using live imaging in PT-derived cells and fresh kidney slices of mouse kidney cortex, we 
discovered that DFX induces rapid swelling of mitochondria, leading ultimately to rupture of 
the mitochondrial membrane. Swollen mitochondria remained polarized but were more 
vulnerable to laser induced damage and oxidative stress. The toxic effect of DFX is not due 
to iron chelation, since other iron chelators did not cause mitochondrial swelling. DFX-
induced mitochondrial swelling occurs in the absence of respiratory chain inhibition and 
oxidative stress, is not explained by a change of inner mitochondrial membrane permeability 
(including opening of the transition pore) and is rapidly reversible. Using electron 
microscopy and intravital multiphoton microscopy, we observed that mice given DFX for 10 
days showed evidence of mitochondrial swelling and dysfunction in vivo, exclusively in the 
PT, as well as impaired solute transport (consistent with Fanconi syndrome). DFX is mainly 
albumin bound in blood, and we found that only the free drug causes toxicity in vitro, which 
might explain why the drug is tolerated by patients. Furthermore, since albumin is actively 
taken up by the PT, this could also explain the localization of DFX toxicity to this nephron 
segment. The established nephrotoxin diclofenac produces a similar phenotype 
(mitochondrial swelling without depolarization), implying a common underlying mechanism 
of toxicity. 
In summary, we found that DFX induces kidney disease due to a novel off-target effect on 
mitochondrial morphology. 
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6 ZUSAMMENFASSUNG 
Akutes Nierenversagen wird zu einem grossen Teil von Xenobiotika verursacht, wobei die 
dahinterstehenden Ursachen oftmals nicht bekannt sind. Der orale Eisenchelator 
Deferasirox (DFX) führt, aus bisher ungeklärten Gründen, in vielen Fällen zu einer 
Dysfunktion des proximalen Tubulus (PT), dem sogenannten Fanconi Syndrom. Zellen des 
PT sind reich an Mitochondrien, für deren normalen Metabolismus Eisen essentiell ist. 
Bisher wurde vermutet, dass sich die Toxizität von DFX auf dessen Fähigkeit Eisen in 
Mitohcondrian zu binden gründet; jedoch zeigen andere in der Klinik verwendeten 
Eisenchelatoren keine Anzeichen dafür, nierenschädlich zu sein. 
Wir konnten mit Hilfe von mikroskopischen Studien in lebenden Zellen des PT und in 
frischen Nierenschnitten des Cortexes der Mäuseniere zeigen, dass DFX zu einem 
schnellen Anschwellen und letztendlich zur Ruptur der Membran der Mitochondrien führt. 
Die geschwollenen Organellen behielten ihr Membranpotential, reagierten aber sensibler 
auf Laser-induzierten und oxidativen Stress. Da andere Eisenchelatoren nicht zum 
Anschwellen der Mitochondrien führten, konnten wir schlussfolgern, dass die Toxizität von 
DFX nicht auf dessen Fähigkeit, Eisen zu binden, beruht. Das von DFX verursachte 
Anschwellen der Mitochondrien trat auf, ohne dabei die oxidative Phosphorylierung zu 
beeinflussen. Ausserdem führte eine Behandlung mit DFX weder zur Induktion oxidativen 
Stresses, noch zur Veränderung der Permeabilität der mitochondrialen Membran. Der 
Effekt von DFX war ausserdem durch die Zugabe von Eisen leicht rückgängig zu machen. 
In Mäusen, die zehn Tage mit DFX behandelt worden waren, konnte mit Hilfe von intravitaler 
und Elektronenmikroskopie exklusiv in Zellen des PT ein Anschwellen der Mitochondrien 
detektiert werden. Zudem war die Aufnahme von Molekülen im PT beeinträchtigt, 
übereinstimmend mit den Symptomen eines Fanconi Syndroms. Wir konnten in vitro 
zeigen, dass nur ungebundenes DFX toxisch ist. In der Zirkulation kommt DFX fast 
ausschliesslich gebunden an Albumin vor, was erklärt, warum DFX von Patienten zunächst 
gut toleriert wird. Da Albumin aktiv in die Zellen des PT aufgenommen wird, könnte es sein, 
dass dies die spezifische Lokalisation der Toxizität in den PT erklärt. Zudem konnten wir 
zeigen, dass Diclofenac, ein bekannterweise nierenschädigendes Medikament, einen 
ähnlichen Phänotyp (Schwellung der Mitochondrien ohne Depolarisation) in unserem 
Zellmodel des PT auslöste. Dies könnte ein Hinweis auf einen gemeinsamen, 
grundlegenden Mechanismus sein. 
Zusammenfassend lässt sich sagen, dass DFX durch einen neuen off-target Effekt auf 
Mitochondrien zu Nierenschädigung führt. 
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